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ABSTRACT  
 
Background:  Hepatitis C virus  (HCV)  infection is a major  world  health 
problem. Gizan region is a rural community in which infectious diseases are 
common, including viral hepatitis mainly hepatitis B (hyper-endemic), and to 
some extent hepatitis C.  
Design: The present study was a case control study  
Setting: This study was conducted at the Microbiology Department at Elemies 
National Hospital  in Sabia, Gizan,  Saudi  Arabia. Polymerase chain reaction 
(PCR) and genotyping techniques were conducted at Alborg Laboratories, 
Jeddah, Saudi Arabia. 
Objectives: This study was conducted to determine the  prevalence of  HCV 
infection  among  pregnant  women, the  predominant HCV genotype among 
infected pregnant and non-pregnant, and to find out whether there is any 
difference  in genotype and subtype among the two study groups .      
Methods:  Five ml of blood samples were obtained from 600 women, pregnant 
and non-pregnant (300 from each group). HCV antibodies were detected in 
plasma by using immuno-chromatography test (ICT) and enzyme-linked 
immuno sorbent assay (ELISA).  All positive and equivocal samples were 
retested for confirmation by polymerase chain reaction (PCR). PCR reactive 
specimens were processed for HCV genotyping by line probe assay (LiPA 
v2.0).    
XII 
 
Results:  Of the 600 blood specimens tested by ICT, 17 (2.83%) were positive; 
8 (2.67%) of which were from pregnant women and 9 (3%) were from non-
pregnant women. Of  the same number of specimens retested by ELISA 
(Human reagents). 16 (2.67%) were positive; 6 (2.0%) were from pregnant 
women and 8 (2.67%) from non-pregnant women, 2 (0.33%) gave equivocal 
results. Of the same number of specimens retested by ELISA (DiaPro Reagent) 
15 (2.5%) were positive; 6 (2.0%) of which specimens were from pregnant 
women, 8 (2.67%) form non-pregnant women, 1(0.17%) gave equivocal result. 
Of the same number of specimens retested by PCR, 13were positive results; 6 
(2.0%) of which were from pregnant women, and 7 (2.33%) from non-pregnant 
women. 
Genotyping results showed that genotype 4 was the major HCV genotype 
among HCV infected women. 
Conclusion: There was neither significant difference in the prevalence of  HCV 
infection between pregnant and non-pregnant women, nor in genotyping, P 
value >0.05, each . 
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 اﻟﻤﺴﺘﺨﻠﺺ
 
ﺗﻌﺘﺒﺮ ﻣﻨﻄﻘﺔ ﺟﻴﺰان .ﻣﻦ اﻟﻤﺸﺎآﻞ اﻟﺼﺤﻴﺔ اﻟﻌﺎﻟﻤﻴﺔ( ج)ﺗﻌﺘﺒﺮ اﻹﺻﺎﺑﺔ ﺑﺎﻟﻔﻴﺮوس اﻟﻜﺒﺪي  :اﻟﺨﻠﻔﻴﺔ
  ﻣﻨﻄﻘﻪ رﻳﻔﻴﺔ ﻣﻮﺑﻮءة 
واﻟﻰ ﺣﺪ ( ب) اﻟﺘﻬﺎب اﻟﻜﺒﺪ اﻟﻮﺑﺎﺋﻲ ﻣﻨﻬﺎ ﻓﻴﺮوسوﺧﺎﺻﺔ اﻟﻔﻴﺮوﺳﻲ   ﻳﺔﺪﻟﻤﻌﻣﺮاض ااﻷﺑﻜﺜﻴﺮ ﻣﻦ 
  (. ج) ﻟﺘﻬﺎب اﻟﻜﺒﺪ اﻟﻮﺑﺎﺋﻲإ ﻣﺎ ﻓﻴﺮوس
  . اﻟﺪراﺳﺔ ﻋﻠﻲ ﻣﻘﺎرﻧﺔ ﻣﺠﻤﻮﻋﺘﻴﻦ ﺗﻘﻮم :ﻧﻮع اﻟﺪراﺳﺔ
ﻣﻨﻄﻘﺔ  هﻠﻲ ﺑﺼﺒﻴﺎ ﻓﻲﻷﻗﺎﻣﺖ اﻟﺪراﺳﺔ ﺑﻘﺴﻢ اﻷﺣﻴﺎء اﻟﺪﻗﻴﻘﺔ ﺑﻤﺴﺘﺸﻔﻲ اﻟﻌﻤﻴﺲ ا: ﻣﻮﻗﻊ اﻟﺪراﺳﺔ
ﻋﻦ اﻟﺠﻴﻦ  ﺗﻢ ﻋﻤﻞ ﺗﻔﺎﻋﻞ اﻟﺰﻣﺮة اﻟﺘﺴﻠﺴﻠﻲ واﻟﻜﺸﻒ آﻤﺎ. اﻟﻤﻤﻠﻜﺔ اﻟﻌﺮﺑﻴﺔ اﻟﺴﻌﻮدﻳﺔ ﺟﻴﺰان ﻓﻲ 
  .ﻓﻲ ﻣﺨﺘﺒﺮ اﻟﺒﺮج ﺑﻤﺪﻳﻨﺔ ﺟﺪة ﻟﻠﻤﺮض اﻟﻤﺴﺒﺐ
ﻋﻨﺪ اﻟﺴﻴﺪات اﻟﺤﻮاﻣﻞ وﻣﻌﺮﻓﺔ ( ج)ﻟﻜﺸﻒ ﻋﻦ ﻧﺴﺒﺔ اﻹﺻﺎﺑﺔ ﺑﺎﻟﻔﻴﺮوس اﻟﻜﺒﺪي ا:أهﺪاف اﻟﺪراﺳﺔ
اﻟﺠﻴﻦ اﻻﺳﺎﺳﻲ اﻟﻤﺴﺒﺐ ﻟﻠﻤﺮض و ﻣﻌﺮﻓﺔ اﻟﻔﺮق ﻓﻲ اﻟﺠﻴﻦ اﻟﻤﺴﺒﺐ ﻟﻠﻤﺮض ﺑﻴﻦ اﻟﺴﻴﺪات اﻟﺤﻮاﻣﻞ 
  .و ﻏﻴﺮ اﻟﺤﻮاﻣﻞ
ﺣﺎﻟﺔ ﻣﻦ اﻟﺴﻴﺪات اﻟﺤﻮاﻣﻞ وﻏﻴﺮ اﻟﺤﻮاﻣﻞ  006ﻣﻞ ﻣﻦ اﻟﺪم ﻟﻌﺪد  5ﺗﻢ ﺳﺤﺐ  :وﺳﻴﻠﺔ اﻟﺒﺤﺚ
ﻗﺎﻣﺖ اﻟﺪراﺳﺔ ﻋﻠﻰ ﺗﺤﻠﻴﻞ ﻋﻴﻨﺎت اﻟﺪم ﺑﺎﻻﺧﺘﺒﺎر اﻟﻤﺴﺤﻲ ﻟﻠﻌﻴﻨﺎت ﺑﻮاﺳﻄﺔ . (ﻤﻮﻋﺔﻟﻜﻞ ﻣﺠ 003)
وﺗﻢ , ﺗﻔﺎﻋﻞ اﻻﺟﺴﺎم اﻟﻤﻀﺎدة اﻟﻤﺼﻮرة  ﺛﻢ إﺧﺘﺒﺎراﻻﺟﺴﺎم اﻟﻤﻨﺎﻋﻴﺔ اﻟﻤﺎﺻﺔ اﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻻﻧﺰﻳﻢ
ﺛﻢ اﻟﻜﺸﻒ ﻋﻦ اﻟﺠﻴﻦ اﻟﺬي ﻳﺸﻜﻞ , ﺗﻔﺎﻋﻞ اﻟﺒﻠﻤﺮة اﻟﺘﺴﻠﺴﻠﻲ إﺧﺘﺒﺎرﺗﺄآﻴﺪ اﻟﻨﺘﺎﺋﺞ اﻹﻳﺠﺎﺑﻴﺔ ﺑﻮاﺳﻄﺔ 
         0.2v APiL(.)ﺴﺒﺔ إﺻﺎﺑﺔ ﺑﻴﻦ اﻟﻤﺠﻤﻮﻋﺘﻴﻦ ﺑﻮاﺳﻄﺔ ﺗﺤﻠﻴﻞ أﻋﻠﻰ ﻧ
% 38,2ﺣﺎﻟﺔ إﺻﺎﺑﺔ أي  71أن ﺣﺎﻟﺔ  006ﻣﻦ اﻟﻤﺠﻤﻮع اﻟﻜﻠﻲأﻧﻪ أﻇﻬﺮت ﻧﺘﺎﺋﺞ اﻟﺪراﺳﺔ  :اﻟﻨﺘﺎﺋﺞ
ﻟﻠﺴﻴﺪات  %(76,2)ﺣﺎﻻت  8ﺑﻮاﺳﻄﺔ ﺗﻔﺎﻋﻞ اﻻﺟﺴﺎم اﻟﻤﻀﺎدة اﻟﻤﺼﻮرة ﺗﻮزﻋﺖ ﺑﻮاﻗﻊ  إﻳﺠﺎﺑﻴﺔ
 .ﻏﻴﺮ اﻟﺤﻮاﻣﻞ اﻟﺴﻴﺪاتﻣﻦ %( 3)ﺣﺎﻻت  9و اﻟﺤﻮاﻣﻞ
إﺧﺘﺒﺎراﻻﺟﺴﺎم اﻟﻤﻨﺎﻋﻴﺔ اﻟﻤﺎﺻﺔ اﻟﻤﺮﺗﺒﻄﺔ ﺑﺎﻻﻧﺰﻳﻢ ﻣﻦ ﻧﻔﺲ ﻋﺪد اﻟﺤﺎﻻت ﺗﻢ  إﺧﺘﺒﺎرهﺎ ﺑﻮاﺳﻄﺔ 
ﺑﻤﺎ  ﻣﻦ ﻣﺠﻤﻮع اﻟﺤﺎﻻت اﻟﻜﻠﻲ%( 76,2)ﺣﺎﻟﺔ إﻳﺠﺎﺑﻴﺔ   61أﻇﻬﺮ ( namuHﻣﺤﺎﻟﻴﻞ ﺷﺮآﺔ )
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 , ﺣﻮاﻣﻞ ﻏﻴﺮﻣﻦ اﻟﺴﻴﺪات %( 76,2)ﺣﺎﻻت  8و ﻣﻦ اﻟﺴﻴﺪات اﻟﺤﻮاﻣﻞ %(2)ﺣﺎﻻت  6 ﻳﻌﺎدل
ﻧﻔﺲ  . ﺑﻮاﻗﻊ ﺣﺎﻟﺔ ﻟﻜﻞ ﻣﺠﻤﻮﻋﺔ ﻣﻦ اﻟﻤﺠﻤﻮع اﻟﻜﻠﻲ%( 33,0)ﻣﻊ وﺟﻮد ﺣﺎﻟﺘﻴﻦ إﺷﺘﺒﺎﻩ إﻳﺠﺎﺑﻲ 
إﻳﺠﺎﺑﻴﺔ ﻣﻦ اﻟﻤﺠﻤﻮع   ﺣﺎﻟﺔ51أﻇﻬﺮت  orpaiDﻣﺤﺎﻟﻴﻞ ﺷﺮآﺔ  ﻮاﺳﻄﺔﺑ ﻋﺪد اﻟﺤﺎﻻت ﺗﻢ إﺧﺘﺒﺎرهﺎ
ﻣﻦ %( 76,2)ﺣﺎﻻت  8و ﻣﻦ اﻟﺴﻴﺪات اﻟﺤﻮاﻣﻞ%(2)ﺣﺎﻻت  6ﺑﻤﺎ ﻳﻌﺎدل %( 5,2)اﻟﻜﻠﻲ 
ﻣﻦ اﻟﺴﻴﺪات  %( ,.71)واﺣﺪة إﺷﺘﺒﺎﻩ إﻳﺠﺎﺑﻲ  اﻣﻞ ﻋﻠﻰ اﻟﺘﻮاﻟﻲ ﻣﻊ وﺟﻮد ﺣﺎﻟﺔﻏﻴﺮ اﻟﺤﻮاﻟﺴﻴﺪات ا
  .ﻏﻴﺮ اﻟﺤﻮاﻣﻞ
ﺣﺎﻟﺔ إﻳﺠﺎﺑﻴﺔ  31أﻇﻬﺮت ﻧﺘﺎﺋﺞ اﻹﺧﺘﺒﺎرات اﻟﺘﺄآﻴﺪﻳﺔ ﺑﻮاﺳﻄﺔ ﻃﺮﻳﻘﺔ ﺗﻔﺎﻋﻞ اﻟﺒﻠﻤﺮة اﻟﺘﺴﻠﺴﻠﻲ أن 
 6ﻣﻦ ﻣﺠﻤﻮع اﻟﺤﺎﻻت اﻟﻜﻠﻲ ﺑﻮاﻗﻊ %( 71,2)ﺣﺎﻟﺔ إﻳﺠﺎﺑﻴﺔ أي ﻣﺎ ﻳﻌﺎدل  61ﻓﻘﻂ ﻣﻦ ﻣﺠﻤﻮع 
. ﻏﻴﺮ اﻟﺤﻮاﻣﻞ ﻋﻠﻰ اﻟﺘﻮاﻟﻲﻣﻦ اﻟﺴﻴﺪات %( 33,2)ﺣﺎﻻت  7و م اﻟﺴﻴﺪات اﻟﺤﻮاﻣﻞ %(2)ﺣﺎﻻت 
اﻟﺬي ﻳﺸﻜﻞ ( ج)أن ﻣﻌﺮﻓﺔ اﻟﺠﻴﻦ اﻷﺳﺎﺳﻲ ﻟﻠﻔﻴﺮوس ( o.2v APiL) إﺧﺘﺒﺎرآﻤﺎ أﻇﻬﺮت ﻧﺘﺎﺋﺞ 
ﻣﻦ %( 33,38)ﺣﺎﻻت  5ﻣﻊ إﺧﺘﻼف أﻧﻮاﻋﻪ ﺣﻴﺚ ﻳﺸﻜﻞ ﻧﺴﺒﺔ  4أﻋﻠﻰ ﻧﺴﺒﺔ إﺻﺎﺑﺔ هﻮ اﻟﺠﻴﻦ 
ﺣﺎﻻت  7ﻣﺠﻤﻮع  ﻣﻦ%(  17,58)ﺣﺎﻻت  5و  ﻣﻦ اﻟﺴﻴﺪات اﻟﺤﻮاﻣﻞ ﺣﺎﻻت إﻳﺠﺎﺑﻴﺔ 6ﻣﺠﻤﻮع 
  .   ﻏﻴﺮ اﻟﺤﻮاﻣﻞ ﻋﻠﻰ اﻟﺘﻮاﻟﻲ ﻣﻦ اﻟﺴﻴﺪاتإﻳﺠﺎﺑﻴﺔ 
ﻓﻲ ﻧﺴﺒﺔ اﻹﺻﺎﺑﺔ ﺑﺎﻟﻔﻴﺮوس  ﻣﻌﻨﻮيﺑﻤﻘﺎرﻧﺔ اﻟﻨﺘﺎﺋﺞ ﺑﻌﺪ ﺗﺤﻠﻴﻠﻬﺎ أﺗﻀﺢ اﻧﻪ ﻻ ﻳﻮﺟﺪ ﻓﺮق : اﻟﺨﻼﺻﺔ
 اﻟﺠﻴﻦ اﻟﻤﺴﺒﺐ ﻟﻠﻤﺮضﻧﻮع  ﻳﻮﺟﺪ ﻓﺮق ﻣﻌﻨﻮي ﻓﻲ وﻻ ﺑﻴﻦ اﻟﺴﻴﺪات اﻟﺤﻮاﻣﻞ وﻏﻴﺮ اﻟﺤﻮاﻣﻞ  (ج)
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CHAPTER ONE  
1. Introduction  
 
1. 1. Introduction: 
  
Viral hepatitis is a general  term  meaning  inflammation of  the liver which can 
 be   caused  by  different  viruses  such  as  hepatitis  A,  B,   C,   D,   E  and  G. 
Development  of   jaundice  is  a characteristic  feature  of   liver   disease,    the 
confirmed diagnosis  can  be  made  by  testing  patient’s  sera for  the presence 
of specific antiviral antibodies (1, 2).   
Hepatitis  C  virus  (HCV)   infection  is a major world  health  problem.  It  has 
a prevalence of about 2% representing 130-170 million  infected people   world- 
wide ( 3).  In  most  cases   (60-85%)  HCV  infection progresses to chronic  liver 
disease, which can lead  to liver cirrhosis and   hepatocarcinoma (3). The  current 
therapy,  based   on  combination  of   pegylated   interferon  with   ribavirin,   is 
effective  in only 50-80%  of  the patients depending on the virus  genotype, and 
has several serious side effects (4). 
 1.1.1 Rationale: 
Pregnant  women  are  considered  a sentinel  population,  because    they  are   a 
relatively unselected group  whose  prevalence data  can be extended to  general 
population (5,6). To our knowledge, no available data  either  for  the incidence of 
HCV  among   pregnant  women, or  the  dominant   genotype  of  HCV   among 
pregnant  women in  Sabia-Gizan;  in Gizan region of  Saudi Arabia. Therefore, 
it is of  interest to run such a study among  pregnant and  non-pregnant  women 
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 1.1.2 Objectives: 
1.1.2.1 General Objective 
To detect HCV infection among pregnant women by detecting  HCV  antibodies 
in  the  plasma by using immuno chromatography test (ICT)  and enzyme linked 
immuno sorbent  assay (ELISA). All  positive results  and equivocal results will 
be confirmed  by  employing  polymerase  chain  reaction (PCR) to detect  HCV 
RNA.  All  specimens  with  HCV RNA  positive  will  be   processed  for  HCV 
genotyping and  subtyping  by using line probe assay (LiPA).     
 1.1.2.2 Specific Objectives 
   1-To  determine the  prevalence of  HCV infection  among  pregnant  women  
      who  attend        antenatal clinics  in Sabia; Gizan, Saudi Arabia.      
   2-To determine the  predominant  HCV genotype (s) among infected pregnant 
      and non- pregnant women by employing  molecular based  techniques.    
  3- To  determine  the difference  in  genotypes  between  pregnant  and  non-    
        pregnant women.             
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 1.2 Literature Review  
Hepatitis  viruses  were  discovered  when  the  first case of post  transfusion 
hepatitis  (PTH) was reported  in the United States by Beeson in  1943,  seven 
cases of PTH  occurred 1- 4 months  after  transfusion of  blood or  plasma were 
reported (7).  
Human  volunteer  transmission experiments  conducted during  World   War 11 
showed  that there were two kinds of  viral hepatitis;  infectious  hepatitis which 
spreads  from  person to  person by  fecal oral route later  known  as (hepatitis A 
virus and hepatitis E virus) and serum hepatitis transmitted by  blood  and blood 
products (8).      
The discovery of hepatitis B surface antigen  opened  the  way  to  develop  tests 
for screening blood donations for the second type of  blood-borne viral hepatitis 
which  was  designated as  hepatitis  B  virus (HBV). This  greatly  reduces   the 
incidence  of  severe PTH. After the implementation of  specific screening  tests 
for  HBV  and  exclusion  of   HAV  as  a cause  of  PTH, it became clear that  a 
substantial  proportion of  PTH  cases  continued  to  occur  were  not  caused by 
HBV or  other  known  viral  agents. This  causative  agent  was  known  as non-
A, non-B hepatitis (NANBH) (9).        
During  late  1970s  and  early  1980s, rates of  NANBH  in  multiple transfused 
patients were reported to be as high as 10%.  Extensive research was  conducted 
in 1970s and 1980s to identify the etiological agent of  NANBH. In  1988, HCV 
was   identified  by  using  molecular  biology  techniques  by   M. Houghton  in 
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association   with   Chiron  and   in   collaboration   with   D.W. Bradley  of   the 
Hepatitis  Branch , the Centers for  Disease Control  and  Prevention  (CDC)  (11). 
These  studies  established  that HCV  was  the  etiological agent of  at  least 80-
90% of residual NANBH (10). 
Hepatitis D virus (HDV) was identified as  a HBV dependant  infectious  agents 
causing   either  a super-infection   during  chronic  HBV  infection  or  as  a co-
infection that occurs during HBV acute infection (11).  Another  etiological agent 
was discovered  by researchers at  Abbott laboratories. They  isolated three viral 
agents   from   a surgeon, whose   initial   name   was   GB. These  agents   were 
designated   as:  GBV-A,  GBV-B and  GBV-C,  and  classified   as  member  of 
Flavivirdae  family  under  Hepacivirus genus (12).  
1.2.1 Hepatitis C Virus (HCV):                                        
Hepatitis C virus  (HCV)  is  small,  enveloped  virus  that belongs to the  family 
Flavivirdae, which is a large family of  related  positive-stranded  RNA  viruses. 
Flavivirdae ( from  the Latin flavus '' yellow''), have  been  classified  into  three 
genera   (Table. 1)   based  on   the  evolutionary   relatedness  of    their   RNA-
dependant  RNA polymerase. These genera  are  Flavivirus, Pestivirus (from the 
Latin  pestis ''plague''), and  Hepacivirus (from  the Greek  hepar, hepatos which 
means  ''liver'') (13). 
The  Flavivirus   genus consists  of  more  than  70 viruses, many  of  which  are 
arthropod-borne   human  pathogens  causing   a variety  of   diseases,  including 
fevers, encephalitis ,and  hemorrhagic fever (14). The Pestivirus genus are animal 
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pathogens of  major economic  importance  for  the  livestock  industry,  causing 
a wide range of  clinical conditions, including acute diarrhea, acute hemorrhagic 
syndromes, and  acute  fatal  diseases. Newly described  pestiviruses of    giraffe 
and  wild  ruminants  indicate  additional  diversity  within  the genus (15).    
Hepacivirus  genus  are   human  pathogens, comprise  HCV and   GBV virus  B 
(GBV-B). The Hepacivirus  genus  shares  many  features  in  common with  the 
Pestiviruses, such  as  genome organization, similar mechanism of  translational 
control, and limited  sequence of  relatedness (16). HCV genome is positive-sense 
single-strand RNA  molecule  of  about  9.6 kb, that  contains a single long open 
reading frame  (ORF). This  ORF encodes  a poly  protein  of  3008-3037 amino 
acids (aa), depending on  the genotype, and flanked by  un-translated regions  at 
the  5' and 3' ends. As  the  result, the  envelope  proteins  and  core  protein   are 
structural   proteins  that  form  the  virus particle,   while   the  remaining   non-
structural  (NS)  proteins  are  required  for   virus replication (17). 
1.2. 1.1 Model systems for studies of HCV cell entry: 
Hepatitis  C  virus  research  was  hampered  for   many years, by  the extremely 
restricted  host  range  and  the inefficiency of  the  in vitro models  based on the 
incubation of the cell  culture with  HCV particles. Therefore, the  establishment 
of    replicon   system   was   a milestone   in   HCV  research (18).  Thus,  several 
surrogate  models were used in studies of  virus  entry  before  the  development 
of an in vitro cell culture  system, allowing  the reproduction  of  all steps of  the 
HCV replication cycle, including cell entry (19). 
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Taxonomic Unit 
 
Representative Examples 
FlavivirusGenus 
    Tick-born viruses
 Malmmalian tick-borne group (15)  
 Seabird tick-borne group (4)            
                                          Mosquito-
borne viruses     
 Aroa virus group (4)                         
         
 Dengue virus group (5)                    
         
Japanese encephalitis group (10)
Kokobera virus group (2)                  
         
Ntaya virus group (6)                 
                
 Spondweni virus group (2)         
               
Yellow fever virus group (9)        
              
Viruses with no known vector 
  Entebbe bat virus group (3)
Modoc virus group (6)                
                
  Rio Bravo virus group (7)         
                 
Unclassified (3)                         
                     
Genus Pestivirus                        
                         
 
Genus Hepacivirus                     
                        
Unclassified (2)  
 
Tick-borne encephalitis virus, Euroean subtype (TBEV-Eu)          
                                                                                                   
Tick-borne encephalitis virus, Far Eastern subtype(TBEV-FE)
Tyuleniy virus
 
Aroa virus
Dengue virus, types-1 to 4 (DENV-1 to DENV-4)                         
                                                                                           
Kedougou virus
Japanese encephalitis virus (JEV)
West Nile virus (WNV)
Kokobera virus
Ntaya virus
Spondweni virus
Yellow fever virus (YFV)
Entebbe bat virus
Modoc virus
Rio Bravo virus
Cell fusion agent virus
Bovine viral diarrhoea virus 1 (BVDV-1), four serotypes
Bovine viral diarrhoea virus 2 (BVDV-2), two serotypes
Border disease virus, two serotypes
Classic swine fever virus (CSFV), four serotypes
Pestivirus of giraffe (unclassified)
Hepatitis C virus (HCV), six genotypes
GB virus (GBV-B)
GB virus A (GBV-A), GBV-A-like viruses
GB virus C (GBV-C), Hepatitis G virus (HGV)
Table 1: Classification  of Flaviviridae family  (adapted from  Lindenbach BD et 
al, 2007)
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1.2.1.1.1 Plasma-derived HCV                                                       
The first approaches for  studying HCV infection  were  based on inoculation of 
primary  human  hepatocytes; T  cells  and  B cells   were  infected with  serum-
derived  HCV (20). The primary limits  of  this system were, the absence  or  very 
low   levels  of   infectious  virus  particle  production,  the  low  level  of   HCV 
replication, which required  the use of  RT-PCR to detect viral RNA in  infected 
cells,  difficulties  in  discriminating  between newly  synthesized  and  input  of 
HCV  RNA.  In addition,  a homogeneous  and  well   characterized   inoculums 
could  not  be obtained due  to  virus heterogeneity and the association  of  virus 
particles  with plasma lipoproteins (21). 
1.2.1.1.2. Recombinant E2 glycoprotein 
A truncated, soluble  form of   recombinant E2  glycoprotein  (sE2) was used  to 
search  for  candidate receptors involved  in  HCV cell entry. These  approaches 
allowed  the  identification of  two major  HCV  receptors: tertaspanin  CD81 (22) 
and human scavenger receptor class B (SR-B1/Cla1)(23). This provided evidence 
for  interaction  of  E2   with   heparan   sulphate  (HS)  proteoglycans  (24).   The 
limitation  of  this  system was  the  fact that viral glycoproteins E1 and E2 form 
 hetrodimer on the viral envelope and  thus isolated  E2 may  behave differently. 
 In  addition  to  hepatocyte,  sE2  binds to various cell lines of human origin (25). 
1.2.1.1.3. HCV-like particles (HCV-LPs) 
HCV-like  particles (HCV-LPs)  produced  in  baculovirus  expression  systems, 
bind  and  enter   into   hepatoma cells  and   human  primary  hepatocytes   in  a 
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receptor-mediated manner (26). These particles were produced using recombinant 
baculovirus  expression vectors and  insect cell cultures, but  it  is not  clear how 
 well  these particles reflect the earliest stages of infection by authentic HCV (27). 
1.2.1.1.4. HCV pseudoparticles (HCVpp) 
HCV pseudoparticle  (HCVpp) system  is based on the  production  of  lentiviral 
particles    that   incorporate   unmodified   HCV  glycoproteins   into    the  lipid 
envelope (28).  Production of  HCVpp  is  achieved by co-transfection of  specific 
cells (293t cells) with  plasmids encoding three components: full-length  E1 and 
E2 glycoproteins, retroviral or lentiviral   core,  polymerase  proteins and  a pro-
viral   genome  carrying   a marker   gene,  such  as   green  fluorescent   protein. 
These particles are infectious and show a tropism for human liver cells. 
Moreover, cell entry of  HCVpp  is  neutralized  by  antibodies  directed  against 
E2 protein. The main disadvantage of this system is that it  mimics only the very 
early  steps  from  viral   binding  to  libration of  the capsid.  Most  importantly, 
unlike  the  natural  virus, HCVpp   are   not   associated   with   lipoproteins (28). 
1.2.1.1.5. Cell culture-produced HCV (HCVcc) 
This model  is  based on  a particular  genotype 2a  virus  strain; JFH-1  genome 
is cloned  from  a serum  of a patient  with  fulminant  hepatitis C. Sub clones of 
human hepatoma cell  line Huh-7  transfected with the JFH   genome  efficiently 
replicate  the  virus  and  secrete  infectious  particles (29).  This  model  has been 
used  largely  for  the  evaluation  of  antiviral  compounds (30).  However, it  has 
some limitation. It is restricted  to  two  particular cell  lines  (Huh-7 and LH86), 
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which  have  abnormal  lipoprotein  metabolism,  also, JFH-1 particles produced 
in  hepatoma  cells  have  a lower   specific  infectivity  than  virus  produced  in 
infected   animal.  Animal-derived  viruses   have   a lower   density  but   higher 
infectivity than  cell culture-produced viruses  (29).  
1.2.1.2. HCV binding and cell entry: 
1.2.1.2.1. Receptor mediated cell entry: 
1.2.1.2.1.1. CD81: 
Tetraspanin CD81 (TAPA-1  is  a widely-expressed  cell surface  protein, which 
is  involved  in  many  activities  such   as   cell  adhesion,  signal   transduction, 
motility metastasis, and cell activation. It is physically associated with  a variety 
of  other  membrane  proteins  such  as  integrins,  linage-specific molecule  and 
other tetraspanins (31). CD81 has been proposed  as an HCV receptor  molecules, 
based on CD81 binding  to sE2.  This binding  appears to be species-specific, as 
sE2 does not bind mouse or rat CD81 (25). 
Several   studies   suggested that   CD81 actually   acts as   a post-binding   entry 
molecule. In  fact,  antibodies  against   CD81  and   human  recombinant  CD81 
inhibit  HCV infection  only  after  virus  attachment (32).  EW1-2wint,  a cellular 
partner  of  CD81  expressed  on  the cell  surface, could  efficiently  block  viral 
entry  by  inhibiting  viral  interaction  with CD81.  The absence of  this  natural 
inhibitor  of  CD81  in  hepatic cells may thus enable virus entry  and  contribute 
to the hepatotropism of  HCV (33). Various  studies elucidated  the cellular  path-
way triggered  by HCV binding to  CD81. Indeed,  engagement  of  CD81 plays 
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a fundamental  role in HCV infectivity through  the activation and relocalization 
of  the  E2/CD81 complex  to cell-cell  contact  areas  where  CD81  comes  into 
contact with tight  junction proteins occluding   and  CLDN-1. These  molecules 
are  described  as  HCV co-receptors. Thus, CD81 is not  only attachment factor 
but  actively  promotes  infection  by  triggering  signaling  cascades  which  are 
important  for  entry of virus and more down-stream events (34). CD81 may  also 
 play  a role  in  the  modulation  of  adaptive  immune  response  through   virus 
interaction with CD81 on  T and  B cells. This, in turn,  could contribute to virus 
persistence and  pathogenesis and, via polyclonal activation of  B cells, to extra-
hepatic  manifestations  frequently  observed  in  chronic HCV infection (35). 
1.2.1.2.1.2. Scavenger receptors:  
Scavenger receptors are  expressed in  various mammalian cells  but  are mostly 
expressed   in  the  liver  and  steroidgenic  tissues. These  receptors  have   been 
categorized into broad classes (A, B, C, D, ect)  according to their structures (36). 
Scavenger  receptor  (SR-B1)  is  a multi-ligand  receptor for various  classes  of 
lipoproteins  (high,  low,  and   very low   density  lipoproteins)   as  well  as  for 
chemically-modified  lipoproteins  as   oxidized   and   acetylated  LDL. Indeed, 
SR-B1  contains binding  site  that  independently  interact with their respective 
ligands (37). The  main function of SR-B1 is  the selective cholesterol  ester (CE) 
uptake from  HDL during  HDL metabolism, also play  important  physiological 
role  in  the  catabolism  of  very  Iow  density  Iipoprotien  (VLDL)  and  in  the 
selective CE uptake from  VLDL,  as recently  shown  in  the studies on primary 
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human hepatocytes (38). SR-B1/Cla1 has been proposed to act as a putative HCV 
entry molecules on the basis of its   reactivity  with   sE2.  SR-B1 binding to sE2 
appears to be species-specific (23). In addition,  natural  serum-derived  authentic 
HCV does  not recognize SR-B1 directly   via   viral    envelope   glycoproteins, 
 instead,  Apo-B lipoproteins associated  with  virus particles  play a key  role in 
the  initial  interaction  of  the  receptor  by  serum- derived  authentic  HCV (39).   
Interestingly, HDL, the main SR-B1 ligand, facilitates HCVpp  and  HCVcc cell 
entry,  with   no  evidence  for   a direct  interaction   between  HDL  and   virus 
particles. It  has  been postulated that the enhancing effects of  HDL on  HCVpp 
and  HCVcc cell  entry could be mediated through either an interaction between 
HDL and lipid membranes or  the activation of  SR-B1 by HDL. HDL decreases 
the  efficiency  of  HCV  neutralizing  antibodies  by  mechanism related  to  the 
stimulation of cell entry (40).   
In contrast with the enhancing effect of  HDL, other natural SR-B1ligands, such 
as VLDL and  oxidized-LDL, has  inhibitory effects on serum HCV and HCVpp 
cell entry via SR-B1(39). Several studies  suggest that  SR-B1/Cla1co-operatively 
interacts   with   CD81   in   HCV  cell   entry.  Indeed,  HDL  enhance  HCVcc 
infectivity only when CD81 was  expressed (41). SR-B1 mediates an arrangement 
of  the plasma  membrane, acting as a major cholesterol  provider and regulating 
the organization of CD81at the plasma membrane, thus boosting permissiveness 
of the cell to HCV infection. The role of SR-B1 was confirmed by findings  that 
high  avidity  membrane  antibodies  directed   against  SR-B1 efficiently  block 
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infection of  hepatoma cells in vitro, even in  the presence of HDL (42),  and  that 
the  expression levels  of  SR-B1 can  modulate  HCVcc  infectivity. These  data 
underline the crucial  role of  SR -B1 in cell infection (43). 
r:LDL recepto .3.1.21.2..1  
LDL  receptor  (LDL-R) is  an endocytic  receptor  that  transports  lipoproteins, 
mainly cholesterol-rich  lipoprotein  LDL, into  cells  through receptor-mediated 
endocytosis   (44, 45).  This   process   involves   the   cell   surface   receptor   that 
recognizes   LDL  particle  (Fig. 1),  followed   by   its   internalization   through 
clarithin-coated pits (46,47).  In 2007, the significance of LDL-R in HCV infection 
of  primary  human   hepatic  cells   has   been   confirmed  (48).   Moreover,   the 
correlation of cell surface expression of LDL-R  in  patients  with  chronic HCV 
infection and  with  high viral load implies that  LDL-R is  actually  involved  in 
the viral replication cycle in vivo. It is conceivable that, similar to SR-B1, LDL-
R  may  participate  in virus cell  entry  via interaction with lipoproteins that  are 
associated with  HCV at early step of infection,  preceding virus interaction with 
CD81. However, one cannot  exclude  the  possibility that  LDL-R  mediates  an 
 alternative pathway of  HCV cell entry (49).    
1.2.1.2.1.4. HCV and exosomes:  
Exosomes  are  small membrane vesicles  in  the  cell  surface,  secreted by cells 
upon the fusion of  multi-vesicular  endosomes (50,51). They  are 60  to 100 nm in 
diameter and originate from late  endosomes.  Exosomes are secreted from most 
hematopoietic  and  epithelial  cells  in vitro. Intracellularly,  they are formed by  
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             Figure 1: Model for cellular uptake of  HCV particles (adapted                              
from Zeisel, M.B, et al, 2007) 
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inward   budding  of  the  endosomal   membrane   in   a process   that   involves 
particular proteins and lipids (52). 
In 2004,  it  has been shown that   HCV  envelope proteins  are  associated  with 
exosomes (53). In the absence of  the  human CD81, HCV  envelope proteins  are 
almost  completely  retained  in  the  endoplasmic  reticulum  of   hamster  CHO 
cells. Instead, when the human CD81is present,  a fraction of the HCV envelope 
proteins passed through the Golgi Apparatus, mature  acquiring complex  sugars 
and is found extracellularly associated with exosomes. It is proposed  that HCV- 
CD81 complex exits  in cells  in  the  form  of  exosome, circulates in  the blood 
as a complex and  exploits the fusogenic capabilities of these  vesicles  to  infect 
cells  even if  there  is  neutralizing  antibodies. Therefore, human  CD81 may in 
fact act as an  exit receptor for  HCV. It is  concluded  that  there  is a fraction of 
HCV RNA bound  to CD81  in patients  infected  with HCV, but it is difficult to 
estimate the exact  fraction of  HCV RNA in  human  plasma  that  is  associated 
with exosomes (53).   
Buoyant density  is the  quality for  a compound  to  rise or  float in  a liquid.  In 
several    studies,   the   buoyant   density   of   exosomes    originating   from   B 
lymphocytes  has  been  determined  to  be in  the  range of  1.08-1.22 g/ml with 
a peak at 1.13 - 1.15 g/ml  (54,55).  Interestingly, hepatitis C  virus  is   structurally 
migrating with buoyant densities lying in  the  same range  as  those  determined 
for low density lipoproteins and exosomes (56, 57).  
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1.2.1.2.1.5. Tight junction proteins: CLDN1 and occuludin: 
Tight   junction   proteins   are   transmembrane  proteins   which  act as a major 
component of  cell-cell  adhesion complexes  that are separated from basolateral 
membrane domain   and     maintain  cell polarity by forming   intra-membranes. 
This  membrane  permits   diffusion   of  certain   molecules  and   limits  others. 
 Hepatocyte tight junctions play a key role in several liver  functions,   including 
  bile formation and secretion (58).  
1.2.1.2.1.5.1. CLDN1: 
CLDN1  is a member  of  the  Claudine  gene   family,  which  is  a new  protein 
involved in HCV entry. It is expressed in all epithelial tissues  but  mainly in the 
liver, forming   networks   at   tight   junctions (59).  Functional  studies  indicates 
that  CLDN1 plays  a role in  post-binding  phase of  infection,  subsequently  to 
HCV  binding  to  CD81 and  probably subsequent to  HCV  binding  to  SR-B1. 
Interaction with  CLDN1 are  thought to take place after migration of  the virus-
SR-B1/CD81  complex  to   tight   junctions (60).   Recent data   indicate that  the 
distribution of CLDN1in tight junctions correlates  with permissiveness to HCV 
infection  thereby  confirming  that   localization  of   CLDN1 tight  junctions  is 
critical  for   viral  entry  and   cellular tropism of HCV (61).  
 1.2.1.2.1.5.2. Occludin:  
An    important   role   in    occludin   is   a trans-membrane   protein    which   is 
structurally  related  to  claudins. This  protein  plays  a major role  in  HCV cell 
entry  and  initiation of  productive HCV  infection (61).  Microscopical   analysis 
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showed that occludin accumulates in  the endoplasmic reticulum  (ER)  and  co-
localizes   with   E2  HCV   protein. The  E2-occludin   association  was  further 
confirmed  by immuno-precipitation  and pull-down assays,  which suggest  that 
occluding  interacts directly with  E2, facilitating viral entry through  hepatocyte 
tight  junctions .This  process may require  a delicate  molecular  architecture  of 
proteins occurring at tight junctions (62). 
1.2.1.2.2. Mechanism of cell entry: 
After  attachment  to  several cell  surface  molecules, HCV is  directed  to  tight 
junction   where   it   interacts   with   CLDN1  and   occluding,  which   directly 
facilitates   its  cellular   uptake. Similar  to   other   flaviviruses,  HCV  entry  is 
 thought to be mediated by  clarithin-mediated endocytosis, with delivery of  the 
viral   nucleocapsid via  early   endosomes. This  mechanism  is   pH-dependant, 
with  an  optimum   pH 5.5,   HCVpp  and   HCVcc  entry  can  be   blocked   by 
substances  that  block   acidification  of  early   endosomes (63).  E1 and   E2  are 
class 11 fusion  proteins. HCV fusion  process promotes  rearrangement of   E1-
E2  hetrodimers  into  its  active form  and  leads to  the  formation of  the fusion 
pore (64). Characterization of   fusion  determinants led to conclusion  that   three 
discrete regions of both E1 and E2  proteins participate in the  membrane fusion 
process (65). Several  hydrophobic patches  have been  identified in  both  E1 and 
E2 glycoproteins (66). However, none of the HCV  receptors has yet  been shown 
to  mediate  viral   fusion. One  study  suggested  that  HCV  cell  entry   is   also 
dependant  on  an intact micro-tubules  network  mainly for  virus nucleocapsid 
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release into  the cytoplasm (67).  A detailed  understanding  of  the mechanism  of 
HCV entry is basic  for development of new  therapeutic strategies to fight HCV 
infection.  Molecules  that  target  the  envelope  glycans (such  as  inhibitors  of 
glycosylation) or  lectins  to  inhibit   virus  binding to cell surface  receptors or  
immuno-sugars have been proposed as  antiviral  drugs (68).  Furthermore,  drugs 
 that  regulate  expression of  HCV receptors at  the surface of  hepatocytes  may 
be used to  block  HCV cell entry. Indeed, alpha interferon, in addition  to  other 
effects,  down-regulates  cell  surface expression of SR-B1 and  LDL-R. Finally, 
any  molecules  targeting   the   microtubule   network  prevent   initiation  of   a 
productive HCV infection and drugs down-regulating hepatic VLDL production 
limit virus propagation by affecting morphogenesis and release of progeny virus 
from infected cells.  In the light of   these currently limited   therapeutic options, 
the need for  more efficacious therapies is more obvious (69). Furthermore,  HCV 
particle   entry   into  the  cell   may  not  be  associated  with  lipoprotein  but  is 
mediated  by  direct  interaction  of  envelope  glycoproteins  with   co-receptors 
HCV particles which are bound by a complex formed  by SR-B1 and  CD81 (41). 
Virus associated with CD81 is subsequently transferred to  tight junctions where 
it interacts  with CLDN1 and  occluding. This model  excludes  the role of  lipo-
proteins in  HCV cell entry  and  corresponds  to  cell  entry  of  HCVpp,  which 
unlike   authentic  HCV, are   not  associated  with  lipoproteins.  However,   the 
envelope-mediated  HCV  entry can  be  indirectly enhanced  by HDL due to  its 
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action on  the  cholesterol transfer  function  of  SR-B1 and can be  inhibited  by 
 oxidized  LDL  (one of the natural SR-B1 ligands) (44). 
1.2.1.3. HCV life cycle:  
After  clarthrin- mediated   endocytosis   and   pH  5.5  dependant   release  from 
endosomes , HCV  translation  and   replication  started  in  the cytosol  (Fig. 2). 
Translation is  initiated  through the Internal Ribosome Entry Side (IRES) in the 
5`  un-translated   region   (UTR)   and    generates   a single   polyprotein   of   a 
approximately  3,000 aa (amino acid)  which  is  cleaved by  cellular   and   viral 
protease into 10 structural and non-structural proteins (70).  
An  alternate open reading  frame  (ORF)  encodes  a short  protein of  unknown 
function. Following synthesis and maturation,  non-structural proteins and  viral 
RNA   form    membrane-associated   replication    complex   can   catalyze   the 
transcription   of   negative-strand   RNA   intermediates  from   which,  in  turn, 
progeny  positive  strand RNA are generated. The capsid  proteins and  genomic 
RNA   assemble  to  form  a nucleocapsid,  which   buds    through   intracellular 
membranes into cytoplasmic vesicles. Enveloped   mature virions  leave the cell 
via the secretory pathway (71). 
1.2.1.4. Translation and proteolytic processing: 
The HCV genome consist of  9.6 kb  positive-strand RNA that comprises a long 
open  reading  frame  flanked  by  5` and  3`UTR (Fig.3). The 5`UTR  is  highly 
conserved  among different  HCV  isolates and contain the internal ribose  entry 
side  (IRES). The  IRES  directly   binds   the   free   40S   ribosomal  subunits.    
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Figure No (2):  Hepatitis C Virus life cycle  (adapted from Bartenschlager R,   
et al. 2004) 
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Figure No (3): HCV genome organization.      (A):  HCV genome  structure and  RNA  elements.   
 B): Polyprotein  processing and cleavage products. Cleavage sites are  indicated, except the NS2/3 
cleavage  is  mediated  by the  NS2 cysteine  autoprotease. (C):  Polyprotein  membrane  topology. 
(adapted from Hijikata M, et al. 1991). 
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The ERIS-40S  complex  binds to the large initiation  factor  elF3 to form  a 48S 
 intermediate   complex  in   which   the   initiation  AUG   codon  at  nt   342  is 
positioned within the ribosomal P-site (72).  The HCV ERIS interacts  with   elF3 
via  determinants  in  domain  111b  and  thereby,  functionally  and  structurally 
mimics the 5`cap-binding  complex  elF4F. Following  the GTP  hydrolysis  and 
recruitment of  a 60S  ribosomal  unit,  the 48S intermediate  is converted  into a 
translationally active 80S complex. The translation of the HCV genome leads to 
a polyprotein  precursor  that is co- and post-translational which  is processed by 
cellular  and  viral  protease to produce  the mature structural  and non-structural 
proteins   (Table 2). The  structural  proteins  core, E1  and  E2  form   the  viral 
particle. The structural region is followed by the P7 poly-peptide (73).  
The non-structural  proteins 2 to 5b coordinate viral replication by the formation 
of  a membrane-bound  replication  complex. Processing  of  the  poly-protein at 
the  core/E1,  E1 /E2,  E2/p7,  and p7/NS2 sites by the host cell signal peptidase 
produces the structural protein  and  p7. There are two viral proteases which  are 
responsible for the  maturation of  the non- structural  proteins. The NS2/3 auto- 
protease  cleaves  at  the  NS2/NS3   junction   while  all  downstream  sites   are 
processed by the NS3-4A serine protease (70).  
1.2.1.5. HCV genome organization:  
The viral  particle consists of  an envelope derived  from host  membranes, into 
which  inserted a variety of encoded  glycoproteins  E1 and  E2, a nucleocapsid 
and    positive-sense,  single-stranded  RNA  genome (74).  The   RNA   genome  
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  Table 2:  Features of  HCV genome and Polyprotein Products (adapted 
from Choo Q et al, 1991)  
Function (s)AA location in 
mature product 
in HCV 
polyprotein 
Nt 
Location 
Genome 
region  
Proteins&  
Initiation of translation, replication‡ 1-3415`UTR
Structural, encapsidation of viral 
RNA‡ 
1-191/179/182342-857C
Structural, receptor binding, cell entry‡192-383915-1490E1
Structural, receptor binding, cell entry‡ 384-7461491-2579E2
possible precursor, structural function384-8091491-2768E2-P7
NK747-8092580-2768 P7
 Part of NS2-3 protease810-10262769-34119 NS2
Part of NS2-3 protease, serine 
protease. Helicase,  NTPase
1027-16573420-5312NS3
Co-factor for NS3serine protease 
activity
1658-17115313-5476 NS4A
Replicase component‡1712-1972 5477-6257NS4B
Replicase component‡ 1973-2420 6258-7600NS5A
RNA-dependent RNA polymerase 2421-30117601-9374NS5B
Replication, packing of viral genome‡ 9375-96213`UTR
  
Abbreviations: NK, not known. 
‡ Putative function based on comparisons with other viruses. 
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contains highly  conserved UTR at the both 5`and 3` termini (75,76)  and flanks a 
large  translation  open  reading  frame  encoding a polyprotein  of  about 3,000 
aa (74). This is  processed  by  both  cellular  and  viral  proteases to  produce the 
specific  viral  gene  products. The structural  proteins, core, E1and E2 proteins 
are  located  in  the  N-terminal  quarter  and  the  non  structural  (NS) proteins 
(NS2, NS3, NS -4A, NS4B, NS5A and NS5B)  in the remaining portion of  the 
polyprotein (77,78).  
1.2.1.5.1. Features of Structural proteins: 
Core Protein:.5.1.1. .1.21  
The core  protein  (aa 191, 21kd)  is  the  first  protein  encoded by HCV  and is 
alternately referred to as C, core, or capsid  protein. It is well-conserved, rich in 
proline  and   basic residue, located  at  the  amino terminus of  the polyprotein. 
Proteolytic processing of C protein occurs in two steps. First, the C/E1 junction 
cleaved by host  signal  peptidase to yield  the  membrane-anchored form of   C 
protein and the  N-terminus of   E1. Subsequent cleavage within the C-terminal 
membrane anchored by the signal peptide peptidase liberates mature form of C 
protein (79). Binding of the core to HCV genome is important to  form  the  viral 
nucleocapsid. The core  protein found  in the  host  cell  nucleus, has biological 
functions, due  to its  ability to bind to ribosome assembled in the nucleus(80). It 
is immunogenic, highly conserved and contains  several  linear  B-cell epitopes 
near  the  N-terminus (81). These epitopes  have  been used extensively for  anti-
body detection in patient sera. In  addition, it  is  a highly   basic protein with  a 
25 
 
hydrophobic region at the C-terminus, which act  as  a signal  for  translocation 
of  E1 to  the  ER  and  essential  for membrane-dependant  processing   of   the  
core (82,83)  
Core  protein is  targeted to the cytoplasmic surface of the  ER, cholesterol-rich 
detergent-resistant membranes, and   lipid   droplets.  Lipid droplets association 
required prior the cleavage with  signal peptide peptidase. It has been  proposed 
that this interaction with  lipid droplets  may be  related to the increased risk of 
liver  steatosis (84). The  core protein  interacts  with  numerous  cellular proteins 
and affects    host   ell  functions  such  as  lipid   metabolism,  apoptosis,   gene 
transcription,  and  various  signaling  pathway  that   play  critical  role  in   the 
establishment of  persistence and disease pathogenesis (85).  
proteins:Envelope glyco5.1.2. 1..2.1 
Envelope glycoproteins E1 and  E2 are type1 transmembrane   proteins with C-  
terminal hydrophobic anchor, released from the viral  polyprotein by the action 
of the host-cell signal peptidase, and have molecular  mass of  31 kd  and 70 kd 
respectively.  E1 and E2  form non-covalent hetrodimers which are  believed to 
represent the building blocks for the viral envelope (86) . 
The ectodomains of  E1 (5 sites)  and  E2 (11 sites) are heavily N-glycosylated. 
Association  between  envelope proteins  is relatively slow and more dependent 
on the folding  of  E1  than  E2. The interaction  seems to be totally membrane-
associated,  because  the   proteins   remain  localized  to  the  ER  and  are   not 
transported to cell  surface. The region for interaction of  E2 with E1 is located 
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in the C terminus, and this interaction requires that both proteins be membrane-
anchored,  possibly  establishing  a temporal  control  on   ER  retention  that  is 
important for folding and association (73).  
Unusually  high  degree  of   amino acid  variation  has  been observed in the N 
terminus  of  E2 protein. This  hypervariable  region, referred  to  as (HVR1), is 
located  between  384-410 aa  of  the  polyprotein. There is a great deal of data 
indicating   that   the   E2  protein   forms   part   of    the  viral  envelop and , in 
particular, that  HVR1 is  presented on  the surface of  the  virion  and  carries a 
neutralization epitopes (87). The HVR1 varies  enormously both within  any one 
isolate,  generating  forms  of  quasispecies, and  between  different  genotypes, 
thus,  it  should  be  stressed  that  no one of  HVR-1 sequence pattern  has been 
associated with  any  particular genotype. Therefore, this region cannot be used 
to make distinctions at this level (88,89). Observations that the specific antibodies 
to  this  region  changes  during  the course  of   infection  suggested  that HVR1 
sequences is  subject to immune pressure with the potential for escape mutants.   
Studies   showed   that   antibodies   in   human  sera  no   longer   recognizes  a 
previously  HVR -1 sequence, but corresponds to a related variant that emerges 
as the dominant viral species during the course of chronic infection (90).  
HVR1-specific antibodies can protect chimpanzees from infection with HCV if 
previously   immunized. An   early   induction   of   HVR1-specific   antibodies 
correlates   with  viral  clearance  in    humans (91).  The   most   striking   recent 
observation for E2  is its putative role in obstructing innate immunity  response 
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to  HCV  replication. E2  contains  a sequence  identical with   phosphorylation 
sites of the Interferon (INF)-inducible protein kinase (PKR), and the translation 
initiation factor, e IF2,  a target of  PKR. This interaction of  E2 and  PKR may 
be one mechanism by  which  HCV escape the antiviral  effect of  interferon (92).  
P7 .3.1..5.12.1 
P7 is (747  to  809 aa, 7 kd ) protein assembles into membrane-bound multimer 
with  potential  ion  channel  activity, and  located at  the  junction  between the 
structural and  non structural region.  It is possible that  P7 is involved  in  viral 
entry. It  is believed that p7 could be important for  viral assembly and  release, 
but  it  is  unknown whether p7 is packaged into viral particle.  Most important, 
pestiviral virons do not contain the  p7 pestiviral homology (93). 
:                                      e Reading Frame Protein (ARFP)Alternativ .4.1.51.2..1
The synthesisof a protein encoded by an  Alternative Reading Frame within the 
core  region  was  reported  by several  groups.  It  was designated  ARFP  or  F 
(frame  shift)   protein  and  comprises  up  to  160  amino  acids. The   ARFP/F 
protein is dispensable for HCV RNA replication (94). 
1.2.1.5.2 .Features of non structural proteins: 
NS2:1.  .5.21..2.1  
The NS2  (810-1.026  aa, 23 kd)  is  a membrane-spanning protein that  contains 
a  C-terminal   cysteine   protease   domains.  NS2/3   junction   is   cleaved    by 
remarkable autoprotease consisting of  NS2 and the  N-terminal  third  of   NS3, 
indicating  that  it  is  oriented toward  the ER lumen (95).  The NS2-3 protease is 
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believed to mediate auto-proteolytic cleavageat the 2/3  site, and requires  Zink. 
The  region  required  for processing has been  shown to lie  between  an active 
residues at  the  C-terminal domain  of  NS2  (His-952, Glu-972, and Cys-993), 
single  residue substitutions in  NS2 region  that  abolish cleavage at  the NS2/3 
site  (96, 97).  However,  this  event is  not   required   for   NS3   serine   protease 
dependent cleavages  downstream, and  mutations inactivating  the  NS3-serine 
protease have no effect on 2/3 cleavage,  indicating that  these  functions of  the 
NS3  protease region are  independent of each other (96,97). 
Studies on  NS2-3 have shown  that, the cleavage at  this site  is virus-mediated, 
and the efficiency  of  in vitro processing is  at  least  partially dependant on  the 
presence  of   microsomal  membranes,  which   varies  among   different   HCV 
strains,  suggesting  the  involvement  of  a cellular  cofactor. I n this  event,  the 
cellular  cofactor   possibly; affecting  the  folding  of   the  precursor protein  or 
stabilizing  the  cleavage  products (98).  It is  not  yet  clear  how  the  N-terminal 
region of  NS3 regulates  NS2/3 cleavage, but it should  be noted  that  cleavage 
is inhibited by NS4A, which allows the N-terminal domain of  NS3  to fold  into 
the compact serine protease structure  (73).  Although NS2/3 protease  is  required 
for  the  replication  in vivo,  it is  dispensable for   replication  of  sub   genomic 
replicons in vitro. It is  unclear  whether  NS2 fulfills any further functions  after 
separation from NS3 (95).   
:NS3 .2.25...12.1 
The  HCV  NS3  (aa 1.027-1.657, 70 kd)  is  a multifunction  protein  because  it 
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harbors a serine protease located in the  N-terminal. One-third of this protein  is 
responsible for  the  down-stream  cleavage  in  the   non- structural  region, and 
a NTPase/RNA  helicase domain in  the C-terminal. Both enzyme  activities  are 
critical for viral  replication (99). For the complete  folding  and enzyme  activity, 
the  serine  protease domain of  NS3 requires interaction with  NS4A, as well  as 
coordination of a structural Zn2+  ion. The serine protease domain is  responsible 
for  proteolytic  processing  of  the entire  down-stream region of  the viral poly- 
protein,  mediate  proteolysis  of   NS3/NS4A,  NS4A/NS4B,  NS4B/NS5A  and 
NS5A/NS5B junctions to release mature NS3, NS4A, NS4B,  NS5A and  NS5B 
proteins (100). The first 181 aa of  NS3 have  been  shown to contain  the  domain 
necessary for all of these cleavages (101).  
Amino acids sequence comparisons of  several HCV isolates  showed  that  NS3 
protein contains three highly conserved residues which are known  to  represent 
a catalytic triad of  the serine proteinaes  family (102,103).  Replacing  substitutions 
for any one of these residues, abolish processing at the downstream sites (104,105). 
The NS3 serine protease  recently  turned  out  to  influence  the  innate  cellular 
host defense by inhibition of  RIG-1 and TLR3  signaling (106). This  observation 
renders  the NS3  protease inhibitors  to emerge as  extremely efficient  antiviral 
components  in  first proof  of  principle studies in  patients  with HCV (107). The 
NS4A  protein  functions   as co-factor  in  NS3  activity.  It is  essential  for  the 
NS3/4A  and   NS4B/NS5A  cleavage  events   to  enhance  the  cleavage  at  the 
NS4A/4B and NS5A/5B sites (108,109). The N-terminal of NS3 have  been  shown 
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to    interact    with    NS4A,   creating    stable    complex    between   the    two 
proteins (110,111,112).  
The crystal structure of  NS3 protease was  clear. One group,  is  a combination 
of  the  NS4A  cofactor peptide in  the complex,  identified a chymotrypsin-like 
protein   (113),  while   a second  group  crystallizing   NS3   protease  alone,  it  is 
indicated that  trypsin-like molecules (114). A previous report has shown  that  the 
NS3-4A complex is  inhibited by chymotrypsin-like  inhibitors  but not  trypsin-
like  inhibitors (115). NS4A is not one  essential  for  all  processing, functions  of 
the  serine  protease  and  it   appears  to  form   an integral  part of  the  protease 
complex (113),  possibly stabilizing  the  protein  in  an active  conformation   and 
directing it  to  membranes where  proteolytic processes take place (116).   
The enzymatic activity of  the NS3 NTPase/helicase is  indispensable for   RNA 
replication. Viral  RNA helicase  is thought to be involved  in  strand  separation 
during   viral   replication  and   transcription (117).  In  general,  helicase  contain 
NTPase   activity,  which  hydrolyse   nucleoside   triphosphates  to  provide  the 
energy  source  for  unwinding  nucleic  acids. It  has been shown that  the HCV 
helicase  has a 3`to5` directionality and unwinds   DNA-RNA  and   DNA-DNA 
substrates  with   similar  levels of   efficiency as  an   RNA-RNA  substrate (118).  
: The NS4 protein .3.2.51.2..1 
The NS4 region of the polyprotein comprises two proteins: 
1.2.1.5.2.3.1. NS4A 
NS4A   is   the   smallest  NS   protein  (aa1658-1711, 8 kd),  that   has  multiple  
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functions in the virus live  cycle. The central  region of  NS4A  is a cofactor  of 
serine   protease  by   enhancing  cleavages  in  cis  and   trans   at  the  NS3/4A , 
NS4A/4B,  and   NS4B/NS5A,  and  NS5A/5B  sites (108,109).  A stable,   physical 
interaction   occurs  between  the  two   proteins   that   can   be  destabilized  by 
mutations  in  NS4A  (110,119).   Furthermore,  NS4A  was   shown   to  intercalate 
within  B-sheet  of  the core; this association  with  NS4A significantly alters the 
structure of  NS3  and  it  is  important  for  the enzyme  activity,  stability,   and 
membrane  association (113).   
Furthermore,  NS4A facilitate recognition of  RNA substrate by  the  full-length 
NS3   protease/helicase.  In  addition,  NS3/4A   complex   anchored  to  cellular 
membranes via  the hydrophobic  N-terminal  region  of  NS4A. The C-terminal 
region  of   NS4A contains a large  number of  conserved   acidic  residues. This 
region  has  been   implicated   in   NS4As   ability   to   promote   NS5A  hyper-
phosphorylation (113).  
1.2.1.5.2.3.2. NS4B 
NS4B (aa 1712-1972, 27 kd)  is  an integral membrane  protein  containing  four 
central   transmembrane  domains    separating  cytoplasmic  N  and   C-terminal 
regions. Due to its very hydrophobic properties, NS4B belongs  to the  difficult–
to-study   HCV proteins that are poorly  understood (120). NS4B is  likely to  play 
a critical role in organizing the membrane-bound replication complex. 
Expression of NS4B is sufficient to induce formation  of  the  membranous  web 
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structures   characteristic of  HCV RNA  replication   complexes.  Furthermore, 
NS4B has been reported to  inhibit the RNA polymerase activity  of  NS5B (121). 
:The NS5 protein .4.2.51.2..1 
This protein contains two important proteins NS5A and NS5B. 
1.2.1.5.2.4.1. NS5A: 
NS5A  (aa 1.973- 2.420, 56-58 kd)   is   a phosphorylated  protein  of   unknown 
functions in  RNA replication. A striking  observation  was  the concentration of 
the  cell  culture  adaptive   replicon   mutations  that    strongly   enhance   RNA 
replication. It has  been  shown  to  interact  with  NS5B  and   inhibit  its   RNA 
polymerase  activity.  Mutations  in   NS5A  that   block  these   interactions  are 
detrimental   for   RNA  replication  (122). 
It  is  a fact  that   NS5A  plays  an   important   role  in  the   regulation  of  viral 
replication  and  a potential role  in  modulating the IFN  response. A number of 
studies  suggest  that  NS5A  is  involved  in resistance  to  interferon  treatment. 
According to one line of  evidence, treatment effectiveness correlates with  high 
mutation rates in NS5A residues (123) . This region is termed  the INF  sensitivity 
determining region (ISDR) (124). 
1.2.1.5.2.4.2. NS5B: 
The sequence of the NS5B protein  (aa 2.421-3.011,68 kd) is  highly  conserved, 
not only between  different strains of HCV, but also in other RNA virus. It has a 
particular amino acid motif which is characteristic for all RNA dependant  RNA 
polymerase (RdRp), thus, its  function  is to  become  the viral  polymerase. The 
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role  of  viral   polymerase  in  HCV  replication is to  convert  the  single-strand 
genome  into  a faithful    intermediate   negative   strand   for   subsequent   and 
repetitive production of positive strands for  virion production (125). This  step  in 
the  viral  replication cycle  is  responsible for the creation of  quasispecies  (126), 
which  refers to  the genetic heterogeneity with an individual that  resulted  from 
infection   with   a heterogeneous  virus    population   or  the   accumulation   of 
mutations that occur over the course of infection because  HCV has  a relatively 
high mutation rate (127).  
:5`UTR .3..5.12.1 
An obvious characteristic of HCV is the (UTR) at the 5` end of  the genome and 
a complete 5`UTR consists of  341 nt  (75).  The  5`UTR  is  the  most  conserved 
portion of the HCV genome (128),  although,  nucleotide variations  characteristic 
of  different  HCV  types exist. These variations have been used  as  a diagnostic 
locus in  genotyping  assays  based  on  polymerase  chain  reaction. The 5`UTR 
contain an (IRES) which permits translation of proteins  from  the  genome  in a 
cap independent (129).   
           3`UTR .4..5.12.1    
  Early analysis of  the  3`UTR  resulted  in  conflicting data regarding  its  exact 
sequence content. Most studies indicated that the  genome terminated a poly (U) 
tract, while one  group  reported  a poly A tract (75).   In 1996, three  independent 
groups  employing   different   experimental  strategies   have  identified  similar 
elements  in  the 3` UTR  of  HCV,  which   are  conserved  between  genotypes, 
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suggesting  that, these elements  are  the correct  sequences for  this  region. The 
3`UTR   contains  (in the  5` to 3` direction)  a region  of   approximately    30 nt 
following  the   stop  codon   of   the ORF, which  shows   nucleotide  variability 
between genotypes, followed by a poly U tract of  variable length,  and  a highly 
conserved 98 base sequence, that represent  the 3` terminus  of  the  genome (76). 
Most of  the nucleotide changes found in the 98-base 3` terminal region  did  not  
affect  the   predicted  secondary  structures, suggesting  that, this  may  play  an 
important role  in replication or stabilization of the HCV RNA. In  addition,  the 
high degree of  conservation at  the 3` terminus  renders  this  region  a desirable 
target  for type-independent diagnostic tests and therapy for  HCV  infection (76). 
1.2.1.6. Genome variation: 
Mutation changes the  amino  acid  sequence,  either  no  effect  on  virulence or 
confers an advantage to the virus such as  that  it can  replicate  more  efficiently 
or evade the  host immune  response,  generating  escape  mutants. Thus, variant 
RNA genomes or polypeptide sequences can  evolve  establishing, in the case of 
HCV, the  coexistence of  several closely  related  but  distinct viruses  within  a 
single   host.  This  viral  population  is  termed  a quasispecies, and  for  HCV is 
commonly based genome variability within the HVR1 (130).   
Sequence variation within relatively well-conserved regions of  the  genome has 
been  extensively studied  and  used as  the  basis for genotypic  classification of 
isolates (131). A system based  on nucleotide  sequence  analysis of  the core,  E1, 
and NS5 regions of the genome has been established, leading to the  designation 
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of  six  distinct  genotypes, which can then be further divided  into subtypes: 1a, 
1b, ect (132). In  the  past  there  is  genotype  7, 8, 9, 10 and 11,  but   the  current 
recommendation  is that genotype 7, 8, 9 and  11 should  be classified  as  a sub-
type of  genotype 6 and 10 should be  classified  as  subtype of  genotype 3  (133). 
Viruses are classified on the basis  of  percentage  homology,  these  homologies 
can vary depending on which genomic regions  which are  chosen. Therefore,  it 
is important to use regions  that have been shown  to be  predictive  of  genotype 
as core, E1, and NS5B. Isolates show  homology of   < 70%   would  be  classed  
as different  genotypes, those with homologies  between  70%  and  85%  would 
be  considered as  belonging  to different  subtypes  within  the  same  genotypic 
group. Viruses within the same quasispecies could show between 98%  to 100% 
homology  in  these  conserved  regions,  and  it  is  necessary  to use  sequences 
 from high   variable   regions,   such   as   the   HVR1,  to   distinguish  between 
 them (134, 135,136,137).  It  has  been  shown that antibodies to core  or NS4  regions 
can be used to distinguish between some  HCV genotypes  because of  variation 
 in the amino  acid  sequence at  the  site  of  reactive  B-cell epitopes. However, 
these  serologica  differences  do not  equate  with  distinct  serotypes  based  on 
antibody neutralization as generally defined for  most  viruses. Because  there is 
as  yet  no  classification  of  HCV on basis of serotyping the  antibody  data  for 
HCV merely represent type-specific  antibody,  which  can  represent   a simpler 
 and quicker way to determine the genotype of a virus (138,139). 
  
36 
 
1.2.2 HCV Infection  
1.2.2.1. Epidemiology: 
Epidemiology    of    HCV   infection   has   significantly   changed    since    the 
introduction  of  HCV  screening  in  blood  banks,  and  a dramatic  decrease  of 
post-transfusion  infections  has been reported (140).  The overall prevalence  rate 
of  HCV (Table. 3) was  estimated  to  be 5.3%  in  Africa, 4.6%  in the  eastern 
Mediterranean  region, 3.9%  in  the  west  pacific  region, 2.15%   in  Southeast 
Asia, 1.03%  in  Europe,1.7%  in America (141). The prevalence  of  anti-HCV  in 
some neighboring Arab  countries and  other Islamic countries  was  reported  as 
follows:  0.2%  in  Algeria, 18.1%  in Egypt,  2.1% in  Indonesia, 0.5%   in Iraq, 
2.1%  in  Gordon, 3.3%  in Kuwait, 7.9%  in Libya, 3.0%  in Malaysia, 1.1%  in 
Mauritania, 1.1% in Morocco, 0.9% in Oman, 2.4% in Pakistan, 2.8%  in Qatar, 
0.9%  in  Somalia, 3.2%   in  Sudan,  0.7%  in  Tunisia, 0.8%    in   United  Arab 
Emirates,  2.6% in Yemen (141).   
Previous  studies  in  Saudi  Arabia indicated that the anti-HCV prevalence  was 
0.4  to 1.7%  among  adults  and 0.1%  among   children.  In Saudi Arabia  HCV 
varied   from   0.9%  in   all   provinces  to  1.9%   in   southern  province.  In   a 
community based  study among  Saudis  from  10 to 50 years  of  age  in  Gizan, 
anti-HCV positivity  increase with age, reaching 3.5% in  people  over  50 years 
of age (142)  
HCV  genotype  determination  assays  can be  particularly  useful  in   studying 
worldwide  and  local  evolutions of  HCV  endemics, therefore, it is  important  
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Table 3:  Prevalence of HCV infection (adapted from WHO et al, 1999).   
 
Prevalence of HCV 
infection 
Country 
0.2% Algeria 
18.1% Egypt 
2.1% Indonesia 
0.5% Iraq 
2.1% Jordon 
3.3% Kuwait 
7.9% Libya 
3.0% Malaysia 
1.1% Mauritania 
1.1% Morocco 
0.9% Oman 
2.4% Pakistan 
2.8% Qatar 
0.9% Somalia 
3.2% Sudan 
0.7% Tunisia 
0.8%  United Arab Emirates 
2.6% Yemen 
0.9%-1.9% Saudi Arabia 
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that    HCV   genotypes   should    be    determined    prior    therapy.   Genotype 
determination  has  implications  for   diagnosis,  and  one   of    important    five 
independent  factors  significantly  associated  with  response  to  treatment  (143). 
1.2.2.2.Geographical Distribution of  HCV Genotype:  
By  analyzing  isolate from  different  areas   around  the world,  more  than  100 
subtypes  have  been described within  genotypes 1,  2,  3,  4,  5 and 6. All geno-
types can be found worldwide, clear geographic distribution of genotype  exists. 
Subtype 1a, 1b, 2a, 2b,  2c,  and  3a account for  > 90%  of   HCV  infections  in 
North  and  South America, Europe, Russia, Australia, China, and New Zealand. 
In  the  United States, genotypes  1a  and  1b  are  responsible for about  80%  of 
the  HCV  isolates. Subtype 1b accounts for  approximately two  thirds of  HCV 
isolates  in  southern  Europe, China,  Russia  and  Japan. Subtype  3a  is  highly 
prevalent  in   Nepal,  Pakistan,  Bangladesh  and   India.  Subtype   4a  is   most 
prevalent in Egypt. In South Africa 50% of HCV infection is due to subtype  5a. 
Subtype 6 is found in South East Asia (131).   
There  are only  few  publications  on  HCV  genotype  determination   in  Saudi 
Arabia, indicating  that  the  predominant genotypes were either 1 or 4  (144). The  
heterogeneity of  HCV genome was described at   the  beginning  of   the 1990s; 
subsequently  genotyping tests  were developed in  order  to   differentiate  these 
variants.  In   1994  a universal  classification  was  considered,  comprising  the 
identification of 6 groups of  viral genotypes (1-6).  Furthermore, >70   different 
subtypes are distributed worldwide. Prior to1994, new variants  were  identified. 
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These  viral  genotypes  were  originally  classified as  genotypes 7, 8, 9, 10  and 
11,  and  were  reclassified   in  2005,  as  follows:  genotype  10a   become   the 
dominated subtype 3K, and genotypes 7a, 7d, 7b, 7e/7c, 11a, 9a, 9b, 9c, 8b   and 
8a became sub-types 6e, 6c, 6d, 6f, 6g, 6h, 6i, 6j, 6 k and  6 l   respectively  (133). 
1.2.2.3. Pathogenesis: 
The mechanism of   HCV  persistence is unknown. The immune response  has a 
unique role in the pathogenesis of viral  hepatitis, because it contributes  to  both 
viral  infection  control, healing  as well as in developing  chronic infection  and 
liver cirrhosis.  HCV is a non-cytopathic  hepatotropic  virus  that  induces acute 
or   chronic  liver  disease  and   interacts  in   a complex  way with  the immune 
system. Interaction between HCV and host immune response  in the first  weeks 
after   exposure   may  substantially   affect   the  subsequent  evolution  and  the 
prognosis of the infection (145). One  to  two  weeks  after  exposure,  HCV RNA 
can  be  detected  in  serum and it  quickly replicates, reaching  serum  levels  of  
around  106 copies/ml.  One   week   post   exposure,  the   rapid   peak  of   viral 
replication  is  followed  by  a period of 4 to 6 weeks  during  which HCV  RNA 
is  slightly  elevated  or  remains   stable, in   the  absence  of  specific  B  and  T 
lymphocyte  and  liver  inflammation  induction (146).   Serum   aminotransferase 
level  begin  to  rise  2  to  8 weeks  after  exposure, and at  8  to 12 weeks,  liver 
enzymes  levels  reach  the  maximum  value, and  HCV  RNA  levels  diminish. 
Anti-HCV  antibodies  presence  is  variable , becoming  detectable  at  the  time 
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of  amino-transferases peak (147).  HCV infection  is  believed  to  be  a relatively 
mild disease compared to hepatitis A or B (148).  
1.2.2. 4. Mechanism of HCV survival in the host: 
The immune response (innate and  adaptive) represents the first line  of  defense 
against viral  replication, HCV  has complex mechanisms to elude  this  immune 
response (149).  
1.2.2. 4.1. Innate immunity:  
The first  mechanism of  host defense against  HCV infection is  represented  by 
innate immune response. This consists  of  endogenous  secretion  of   interferon 
and   natural   killer  cells  (NK).  This  virus   causes   early   alterations  in   the 
expression of   several  hepatocytic   genes,  especially  in   those  related  to  the 
response to  interferon type 1. Double stranded RNA-dependant   protein  kinase 
(PKR) and Mx protein are produced (147).  
HCV  can  reduce  the  intracellular production of interferon α by the  inhibitory 
effect   of    non-structural   proteins  (NS3,   NS4A  a nd  NS5A),  aided  by  the 
regulatory  factors  of   interferon  production. Viral envelope proteins (E2)  and 
also  NS5A  inhibit  the  activity  of   double-stranded RNA  dependent   protein 
kinase in vitro, which is one of  antiviral proteins  stimulated by  interferon  (145). 
Viral  proteins  also influence the  activity of  NK cells. HCV envelope  proteins 
bind to the surface of NK cells blocking  their activation and cytokine secretion. 
 Dendritic  cells contain a heterogeneous population of antigen  presenting cells, 
playing a critical role in alerting the immune system to  the  present  situation of 
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ongoing  viral   infection. To  produce  interferon  type 1, that interacts with NK 
cells, presents the  antigens to CD4 and  CD8  lymphocytes (149).  Impairment  at 
various  stages  of  the interaction between  antigen presenting cells and  T  cells 
 can severely impair  the ability of  the host  to  clear  the infection, and promote 
persistence to the infection (150). 
1.2.2. 4.2. Adaptive immune response: 
1.2.2. 4.2.1. Cellular immune response  
It  has  been  demonstrated  that  an early, strong, polyclonal and   multi-specific 
response  of    CD4+   and   CD8+  T   lymphocytes   is   correlated    with    viral 
clearance   (151).  Secreted  cytokines  profile  influence   the  evolution  of  HCV 
infection. T helper 1 (Th1) and cytokines stimulate cytotoxic CD8  lymphocytes 
while T helper 2 (Th2) cytokines  stimulate antibodies production.Th1cytokines 
secretion  response has been associated with healing  after  acute   infection  (152). 
Data regarding the  persistence of  T  lymphocyte response after acute  infection 
is controversial and suggests that   while  CD4+ T lymphocyte  response persists 
several  years   after  acute  infection, CD8 T   lymphocyte  response  disappears 
shortly after acute infection (146). 
Hepatitis C  infection impedes the early stages of  adaptive   immune  activation 
by  altering  dendritic  cell   function. Dendritic  cell  in  the  presence  of   HCV 
peptides  have a limited  ability  to  stimulate  antigen-specific  response  by  the 
main components of the adaptive immune response  (functional  helper CD4+ T 
cells and effecter CD8+T cells).  Part  of   this  dysfunction probably lies  in  the 
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altered  cytokine-secretion which  leads to defective T cell  activation.  Hepatitis 
C tends to become chronic, if the immune response is late, less efficient  against 
lower number of  viral  epitopes and does not persist for a sufficient period  (150). 
1.2.2. 4.2.2. Humoral immune response  
Anti-HCV   specific  antibodies  become  detectable  in   serum   after   cellular 
immune response and  aminotransferase elevation (147). The inability of the host 
to  mount  an  effective humoral  response against HCV might  be  partly due to 
interactions  between  viral  proteins  and  putative cellular receptors. The virus 
envelope proteins (E2)  have critical residues which are important for the initial 
steps of viral binding to  hepatocytes. A high rate of mutation within E2  HVRs 
results  in  the  production of   HCV  variants  that  impair  the  recognition   and 
binding of neutralizing  antibodies.  These data support the  quasispecies  nature 
of   HCV and  the   selection  of   strains  to  avoid   immune   pressure.   It   also 
emphasizes the  possible role of  genetic heterogeneity of  HCV in escaping  the 
immune system (153). 
In  addition,  extensive  glycosylation  on   E2   in  the region close to  the CD81 
binding site impairs  antibody-mediated inhibition of viral  attachment  to  HCV 
putative surface receptors. Although antibodies to HCV proteins  (core and non- 
structural  proteins), are  not found on the surface of  the  virion or contribute  to 
viral neutralization, they are not inhibited by virus attachment (35). 
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1.2.2.5. Type of HCV infection:        
1.2.2. 5.1. Acute HCV infection: 
HCV causes acute hepatitis, but  due  to  the  subclinical  or  mild nature  of  the 
illness, most  cases go unrecognized.  Acute hepatitis C  is symptomatic in  25% 
to  35%  of  cases (154),  and the incubation period  is usually  6 to 10 weeks  (155). 
The clinical features resemble  those  of   other  forms  of  acute viral   hepatitis. 
Symptoms  include  malaise, nausea,  right  upper  abdominal  discomfort,  pale 
stools, dark  urine and  jaundice. These symptoms are usually mild  (156).   
Small  proportion of  patients resolve  infection and  clear  the virus. It  has been 
proposed  that a significant difference in  the host cellular and humeral  immune 
response   occurs (157).  Viral  clearance  occurs   before   a measurable   humoral 
response or even in its  absence. Therefore, there is small proportion of  patients 
who  are  negative by  EIA  tests  for  HCV  antibodies  during  the acute   phase 
and  heal  without  developing  any  detectable  serologic  marker  of   infection. 
However, most  of  the  patients with acute HCV infection will develop  chronic 
liver disease (158). 
1.2.2. 5.2. Chronic HCV infection: 
 and  patients  of ajoritym the  resolve in  to  fails infection CV H ,exposure  Post
therefore  (approximately 80% - 85%)  become chronically infected with  HCV. 
Chronic  HCV  infection  persists for  more than 6 month  and  the term  chronic 
infection  specifically indicates the duration of  infection and not to  the severity 
of  the  disease. The mechanism underlying   the  failure  of  viral  clearance  are  
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unclear (159). After  initial  HCV infection, there  is a quiescent period of 8 to  12 
weeks  before  symptoms of  hepatitis C are  manifested. Symptoms  depend  on 
the  stage of  the  disease  and  they  range  from  mild, moderate or severe.  The 
disease is  most  often  asymptomatic but  significant morbidity occurs in  about 
one-third   of   patients.  The  main   symptoms   are   fatigue  lethargy,   nausea, 
anorexia  and  a tendency to  fluid  retention  with oedema, abdominal   swelling 
and  signs of  coagulation disorder  such as  bruising  and  epistaxis. Jaundice  is 
seldom  evident  in  chronic  hepatitis  C  until  very  late  in  the  course   of  the 
 disease (154). Depending on the extent  of liver  damage,  chronic  hepatitis  C  is 
 broadly classified  as chronic  persistent  hepatitis  (CPH)    and  chronic  active 
hepatitis C  (CAH). In  CPH, liver  damage  is  relatively  minor  and reversible, 
while  in   CAH,  liver  damage   increases  more  rabidly  and  more   frequently 
progress to   cirrhosis   (160). In  fact,   spontaneous   resolution  of  chronic  HCV 
 infections occurs at  rate of  0.5%  to 0.74%  per person/year (161).  
Unfortunately, up to 20%  of individuals with  chronic HCV  eventually develop 
liver cirrhosis, that may be  complicated  to Hepatocellular  Carcinoma   (HCC), 
or hepatic decompensation that may  include  spontaneous  bacterial  peritonitis, 
hepatic hydrothorax, ascites, variceal hemorrhage or death (162).  
1.2.2. 5.3. Chronic HCV co-infection with HBV: 
Many  studies have shown that  HBV  could  be  detected  in  HBs Ag   negative 
patients  with  or without   serological  markers  of  pervious  infections  that   is 
known  as  Occult  HBV infection (163,164). Some  observations  have  suggested    
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that  the lack of   HBs Ag may be due to genome  rearrangements  that  interfere 
with  gene expression and  leads to the production of  an antigenically  modified 
S protein  (165,166).  
Occult  HBV infection  has  frequently been identified in patients  with   chronic 
HCV  infection and considerable data  suggested that this occult  infection   may 
contribute  to  chronic  liver  damage   and  the  development  of   hepatocellular 
carcinoma  (167).  One   third  of   patients  with  chronic   hepatitis  C  virus   had 
detectable  HBV  genomes, despite  the  absence  of  circulating   HBs Ag.  This 
incidence  is  significantly  higher than that among HCV-negative  patients  with 
chronic  liver disease. The prevalence of occult  HBV  infection was particularly 
high among patients with anti-HBV antibodies (165).   
1.2.2. 5.4. Extra hepatic manifestation:  
Infection  with   HCV   mainly  affects  the   liver,  but   there  are  many   other 
conditions  which  are  associated  with  HCV  infection.  Several   extrahepatic 
manifestations  (EHM)   have  been  reported  in   the  natural  history  of   HCV 
infection (168).  According to various studies, 40-74 %  of patients  infected  with 
 HCV   might   develop   at   least   one   of   EHM   during    the  course  of   the 
disease (169,170).  Infected  extrahepatic tissues might acts as a reservoir  for  HCV 
and play a role  in  both HCV persistence and reactivation  of  infection  (171). An 
important feature of HCV is that  the virus avoids immune  elimination and  that 
 may   result    in   chronic   infection,   accumulation  of    circulating   immuno- 
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complexes and autoimmune phenomena. This virus shows  a particular lympho-
tropism  other  than  hepatic tropism,  that  is  responsible  for  many  EHM (172). 
1.2.2. 5.4.1. Mixed Cryoglobulinemia:  
Mixed Cryoglobulinemia (MC) is one of the common disorder   associated  with 
HCV  infection  (173,174) .   Cryoglobulins   are   abnormal   immunoglobulins  that 
reversibly  precipitate  or  clump  together  at  temperatures  lower  than  37°C.   
MC  is   characterized by  the  deposition  of   circulating  immunocomplexes  in 
small   and   medium  sized  blood  vessels  resulting  in   clinical   manifestation 
(asystemic  vasculitis)   (175,176).  More  common  symptoms of  MC   are  general 
malaise, arthralgias and weakness. Skin is commonly  involved  with  cutaneous 
 vasculitis  ranging  from  purpura to necrotic  ulceration (177).  Furthermore,  the 
most   serious   complication   of   organ   involvement  in  MC   is   a peripheral 
neuropathy (178.179).   Cryoglobulinemia   can   affect   the   kidneys   leading    to 
membranous proliverative glomerulonephritis (180).   
1.2.2. 5.4.2. Lymphoproliverative disorders: 
Few studies  reported  association  between  HCV  infection   and  non-Hodgkin 
lymphoma (NHL)  (181,182). Viremia due to   hepatitis C  has been reported  in  up 
to  35%  of  patients with  B cell  lymphoma and almost 90%   of  NHL  patients 
with cryoglobulinemia (183). 
1.2.2. 5.4.3. Dermetological manifestations:  
1.2.2.5.4.3.1. Porphyria  cutanea tarda  is skin disorder. The prevalence of  HCV 
 infection   in   patients  with   porphyria  is   high, 40 - 50%  depending  on   the 
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country (184,185).   Some  authors  suggested  that  porphyria  cutanea tarda  might 
be related to HCV induced hepatic iron overload (186).  
 1.2.2. 5.4.3.2. Lichen  planus  is skin disorder. Hepatitis C-related lichen planus 
is caused by HCV replication in skin epithelial cells (187).  
1.2.2. 5.4.4. Endocrinological manifestations: 
1.2.2. 5.4.4.1. Thyroid  disease  is  more commonly  seen  in  people  with  HCV 
than in general  population. About 13%  of  HCV infected  patients have   hypo- 
thyroidism and up to 25% have thyroid antibodies (188). 
1.2.2. 5.4.4.2.  Diabetes  Mellitus  (DM)  is  found  more   commonly   in   HCV 
infected  patients.  Some  authors  reported  that  DM  in   the  course   of   HCV 
infection was associated with advanced liver fibrosis or cirrhosis (189).  
1.2.2. 5.4.5. Rheumatologic  manifestations:  
Arthralgias    and/or   arthritis  are  found   in  up   to  74%   of    HCV   patients, 
characteristic lymphotropism of  HCV is  the basis of  the  increased  production 
  of  auto-antibodies (172). 
1.2.2. 5.4.6. Other syndromes: 
Other  syndromes  related  to  HCV  chronic  infection are Idiopathic pulmonary 
fibrosis (190) ,  Hypertrophic and dilative cardio-myopathy (191),  Mooren  corneal 
ulceration (192) and Osteosclerosis (193). 
1.2.2. 5.5. Progression of HCV infection:  
1.2.2. 5.5.1. Steatosis 
Steatosis (fatty liver)  defined as an increased  fat  (triglycerides ) content of  the 
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liver, it is a common lesion associated with many conditions affecting  the liver, 
like alcohol consumption and over  weightiness. Interestingly, the proportion of 
HCV infection with  steatosis is higher than  one would predict (194,195). HCV  is 
thought to induce steatosis by interfering with  lipid  secretion and  degradation 
and  by  increasing lipid  synthesis leading  to  accumulation of  triglycerides in 
hepatocytes. The prevalence of  steatosis in  patients with HCV infection varies 
between 40% and  80%, depending on the features of the population studied  in 
terms of alcohol consumption,   diabetes, obesity, and other risk factors of fatty 
liver (196). 
The  HCV  core   protein, is  localized   at   the  surface  of   lipid  droplets  and 
mediates  viral   assembly  in  close  association  with   the  cellular  fatty  acids 
metabolism  (197),  as  well  as  some  HCV non-structural   proteins,  have  been 
shown to interfere with  VLDL secretion (198,199).  HCV  infection also regulates 
lipid  synthesis  (200), inhibits  fatty  acids  oxidation (201)  and increase release of 
fatty acids from adipocytes (202).  
The two important  observations is that the severity of  steatosis correlates with 
the level of  HCV replication, expressed as  HCV RNA  level  in  the  liver  (203) 
or serum mainly in HCV genotype 3 (204).  The second observation is  that, fatty 
liver is significantly reduced or disappeared when patients are treated with anti-
viral. This effect again, is more evident in patients with genotype 3, while those 
with  other  genotypes, the  level  of   steatosis  remains  low  even  in  case   of 
sustained virological response (205,206).   
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1.2.2. 5.5.2. Fibrosis: 
The  vast  majority  of  cross-sectional and longitudinal studies have repeatedly 
shown  an  association  between  steatosis  and  progression  of  liver fibrosis in 
HCV  infected  patients  (207,208,209,210).  The mechanism by  which  HCV-related 
steatosis    promotes   liver   fibrosis   suggested   that    oxidative   stress,   pro- 
inflammatory   cytokines,  insulin   resistance  and   increased   susceptibility to 
apoptosis  mediate  the  fibrogenic  effects of   steatosis. HCV  infection  in  the 
presence  of   steatosis and increased apoptosis is  associated  with activation of 
 stellate cells and increased stage of fibrosis (211). 
Serum   aminotransferase  elevations  dose   not   correlate   with  inflammatory 
presence of  fibrosis, because serum  biochemical  markers of   hepatic  fibrosis 
have   not    proven  to   be   reliable   in   predicting   the   severity   of   hepatic 
inflammation or fibrosis  (212). Viral load   also does not correlate with presence 
of  fibrosis. Liver biopsy is  the only  way to  assess severity of  the  disease.  It 
provides important  information  regarding whether to  initiate  medical therapy 
and  whether to persist  if  therapy is  poorly  tolerated  unless  there is a contra-
indication.  Liver  biopsy  must  be  performed  in  patients  for  whom  medical 
therapy is contemplated (213).  
1.2.2. 5.5.3. Hepatocellular Carcinoma:        
Chronic HCV infection  is  characterized by  inflammatory  lesions in  the  liver; 
often combined with intra-hepatic lipid  accumulation  and  progressive  fibrosis 
of   variable   degrees,   and   long   term   progression   to  cirrhosis  and    HCC 
50 
 
(Fig. 4) (214,215). HCC incidence has increased sharply over recent decades; each 
year 4-5% of patients with chronic HCV infection develop HCC (216). 
The average duration of  infection before the onset of  cirrhosis is  20 years, the 
range  is   wide,  and  HCV  infection  may  be  present  for  50 years before the 
 identification of cirrhosis  (217).  Factors  that contribute  to  the development of 
cirrhosis are unclear. Clinical studies suggest that the risk of  HCC development 
is associated with  certain HCV genotype (218). Other  factors  include  older  age 
male   ,)212(consumption   lcohol a  ,)20(2infection    of duration    ,)19(2 )years 55 >(
sex (222),  obesity (223),  diabetics  mellitus (224)  and  co-infection with HBV  (225).  
HCV  is the only RNA virus  with a predominantly cytoplasmic life  cycle  (226). 
All potentially pro-oncogenic events are, therefore, likely to be restricted  to the 
cytoplasm,   suggesting  indirect   mechanisms  of  hepato-carcinogensis.  While 
HCV  infection leads to chronic inflammation,  steatosis, fibrosis  and  oxidative 
DNA damage, several HCV  proteins  have  direct  Oncogenic  effects  and   up-
regulate  mitogenesis (227,228).  The  accumulation  of  oxidative stress  and  DNA 
damage in a setting of restricted cell cycle, check point control  and  accelerated 
cell  division, is  thought  to compromise  gene  and  chromosome  stability  and 
form  the genomic basis for the malignant transformation (229).          
In  a part  of  complex  interactions,  HCV  proteins  interact  with  a number   of 
host factors and  signaling pathways,  thus  contribute  to  the  progression  from 
chronic   hepatitis   C  to  liver  cirrhosis   and   HCC (230).  By  modulating  gene 
 transcription and  translation  as well  as   post-translational   events,  the  viral   
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Figure No 4:  HCV-induced hepatocarcinogenesis (adapted from Koike, K et 
al, 2009) 
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proteins  interfere  with  innate  immunity  to favor viral   persistence  and   liver 
inflammation.  In  addition,  the  altered  cell  signaling, membrane   physiology, 
apoptosis   and    proteins   trafficking,  induce  oxidative   stress,  and   genomic 
instability  as  well  as  malignant   transformation.  Among  the  HCV  proteins, 
Core,  NS3, NS4B  and  NS5A  are shown to have transforming  potential  when 
transiently or stably expressed in cell culture (231,232). 
Surgical  therapy  (resection  or  liver  transplantation) of  HCC  offers  the  only 
hope for cure, therefore, HCC must be identified early before vascular  invasion 
and   metastasis. As  patients   with  cirrhosis  in  whom   surgery  is  an   option, 
screening  for  HCC  should  be  undertaken.  Although, the  optimal   screening 
regimens  in  these patients  is  unknown, semiannual visualization  of  the  liver 
using ultrasound, triphasic   computed tomography scan, or magnetic  resonance 
imaging (MRI) with gadolinium is prudent (233). 
1.2.3. Laboratory Diagnosis of HCV infection 
Diagnosis of  HCV infection  is  still  problematic, due  to  number  of   reasons: 
firstly,  there  are  non-specific  diagnostic  tests,  and  serum  markers  currently 
used that cannot differentiate between an acute  or chronic  HCV  infection  (234). 
Anti HCV IgM   determination has  not  proved to be  useful  in  the diagnosing 
of  acute  HCV  infection  because   these  antibodies  are   present  in   a similar 
concentration in both acute and chronic infection (234).  
Acute HCV  infection  cannot be   diagnosed depending  on  clinical  signs  and 
symptoms  only,  because  this  infection  is  always asymptomatic or with  non-
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specific signs and symptoms and  rarely recognized based on these criteria.  An 
exception  is  the  early  diagnosis  of  acute  HCV infection through systematic 
screening in a symptomatic patients exposed to known risk factors (235).        
HCV  infection can be detected by different methods. These methods can either 
by serological  tests  which detect  antibodies or  by the  means  of  nucleic acid 
tests  which  detect  HCV  RNA. The  virus  cannot  easily  be  isolated  in  cell 
culture  because  it  cannot  be  propagated  in  conventional  cell culture. These 
methods  are  used to diagnose acute and chronic HCV infection. Only  patients 
with  detectable  HCV  RNA  should  be  treated. HCV  genotype is a clinically 
useful tool; as it works as  a predictor of  interferon  response  and  indicator  of 
disease outcome (236). 
Patients suspected with acute infection should be tested for  HCV antibodies by 
Enzyme  Immune  Assay ( EIA ) and  confirmed  reactive  by  the  detection  of 
HCV  RNA by PCR. The presence of  HCV RNA in the absence of  HCV anti-
bodies  is  strongly  indicative  of  acute  infection. It  is  difficult to distinguish 
between   acute   HCV  infection   and   acute  exacerbation  of   chronic   HCV 
infection (236).  Acute  hepatitis  C  confirmation is  unlikely if  both  HCV  anti-
bodies and HCV RNA are  undetectable, and it  is also  unlikely  to confirm the 
presence of  HCV antibodies in  the absence of  HCV RNA. HCV RNA can  be 
temporarily  undetectable due to  transient or  partial control of viral replication 
by    the  immune  system   before  replication   stops  and  chronic  infection  is 
established.  Furthermore,  the  presence of anti-HCV antibodies in the absence 
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of   HCV RNA  is  generally  observed  in  patients  who  recovered from  a past 
HCV  infection.  Nevertheless,  this   pattern  is  similar   to  false  positive  EIA 
 results (237).  
Detection of  HCV RNA in  the absence of HCV antibodies is exceptional with 
current   third   generation  EIAs,  usually  observed   in   profoundly   immuno- 
depressed  patients, hemodialysis, or  agammaglobulinemic subjects (238).             
1.2.3.1. Serological Tests: 
1.2.3.1.1. Enzyme Link Immune Sorbent Assay (ELISA): 
Enzyme  linked   immune   sorbent   assay  (ELIAS)  (Fig.  5)   started   as   first 
generation of  anti-HCV enzyme immune assay  (HCV 1.0 EIA)  in 1990.   This 
method detects antibodies to an antigenic  protein  (c100-3)  derived  from  non-
structural   protein  (NS4)  of   HCV. Even   though   this   assay  facilitated  the 
screening of anti-HCV antibodies, it did not detect all the relevant patients,  and 
had  a protracted  window  period of  infectivity ranging from 12 weeks  to  >26 
weeks post infection (239).  
The development of  the  first  generation  tests was  considered  a major  break- 
through despite that  it  is only detected in 60-80%  of  infected  individuals  and 
in  acute  cases  it  took  about  6  months  before  a good   majority  of   patients 
showed  evidence of   seroconversion (240). A second   generation anti-HCV  EIA 
(HCV 2.0  EIA)  was Licensed in  1992.  This  test  incorporated  two additional 
proteins; one  structural  (c22 -3)  of  the  core  protein  and   one  non-structural 
proteins (NS3)  (c33c). This test was substantially more sensitive than HCV 1.0  
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Figure 5: Different EIAs Generation: (adapted from Younossi Z M & 
McHutchinson JG. et al, 1996)  
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EIA  in detecting antibodies during  acute and chronic  infection.  Antibodies  to 
c33c proteins appear much earlier than those to c100-3, thus the seroconversion 
window  period  could  be  shortened  by  10-20 weeks. In addition,  comparing 
first  generation  to second generation tests showed that HCV 2.0 EIA  detected 
additional HCV chronically infected patients at a higher rate (239).  
Conflicting   estimates   were  reported   regarding  the  residual  risk  of   HCV 
infection after implementation of the second generation assay. Projection based 
on  incidence-window  period  models  suggested that  the  risk  of  HCV  post-
transfusion   hepatitis   had   dropped   to < 1   in  100000 (241). There has been a 
gradual    improvement  in   specificity   in   the   first   generation   and  second 
generation tests, with specificity exceeding 99%  (242). 
The third generation  screening test  (HCV 3.0 EIA)  was  licensed in 1996, and 
can detect antibodies to an even  greater number of  HCV-encoded  epitopes. 
This  test  differ s  in  antigen  content   from   the  earlier-generation  screening 
assays. It   contains  the   c100  recombinant  protein  in   addition  to  the   NS5 
recombinant protein. This allows the detection of antibodies to extra number of 
HCV-encoding epitope  that leads to an increase in  the sensitivity of  HCV 3.0 
EIA. This consequently narrowed  the  seroconvertion window period by about 
10 days  compared  to that of  HCV 2.0 EIA  (243).  Third generation testing was 
shown   to   resolve  the  status    of   high  proportion  of   samples  that    show 
indeterminate  results  in  the  second  generation  assay. However,  it  also  has  
generated a number of indeterminate results in previously negative results  (244).   
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Sensitivity  of   an   anti-HCV  assay  can  be   defined   as  its  ability  to detect 
reactivity in specimens from subjects who  have been  infected with  HCV. The 
specificity  is  defined  as  the  ability  of  the assay  to  show  non  reactivity  in 
specimens from subjects who  have  never  been  infected  with  HCV (244). This 
phenomena  improved considerably with  third  generation  assays, largely  due 
to inclusion of  c22-3 (core)  antigen. The inclusion of c33-3  allowed detection 
of  about 12-20%  of  infected individuals.  Third generation assays  marginally 
increased  sensitivity  and   further   reduce   the  window   period   after   acute 
infection. These improved characteristics are mostly due to antigen modification 
 and   plate   coating concentrations rather than the addition of NS5 antigen (245). 
1.2.3.1.2. Anti HCV supplemental assays:        
1.2.3.1.2.1. Recombinant immune Blot Assay (RIBA):  
The  recombinant  immune blot  assay (RIBA)  is  an anti-HCV   supplementary 
assay. In  this  test  the  proteins  are  blotted  as  individual  bands  onto  a nitro-
cellulose  or   nylon  strip. Several   generations  of   immune   blot   have   been 
developed to resolve the problem of EIA non-specificity (246).  
The Chiron RIBA HCV 2.0 strip  (RIBA 2.0)  was  licensed in June 1993.  This 
immune  assay contains recombinant  HCV encoded   antigens  fused  to  human 
Super  Oxide Dismutase  (hSOD). The  recombinant antigens c33c and NS5 are 
fusion  proteins. The  recombinant  hSOD  is  included on RIBA strips  to detect 
non-specific antibodies which are immobilized on nitrocellulose strip (247).   
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The  negative, intermediate, or positive interpretation of results is  based  on  the 
reaction  pattern  present on the strip. RIBA  is considered positive if  there  are 
reactions with at least  two antigens with intensities greater than or equal to that 
for  the  week  IgG  control and no  reactivity  with  hSOD  (247).  About   89% of 
RIBA  2.0 positive specimens are  HCV RNA-positive  by PCR,  while  19%  of 
RIBA 2.0  intermediate specimens are HCV RVA-positive  by  PCR  (239). Third 
generation  assays  are  currently  available. Chiron RIBA  HCV 3.0 SIA (RIBA 
3.0)  has  been licensure in  1999. This  assay uses a mixture of peptides, rather 
than antigens, (recombinant ), for the5-1-1/c-100 and c22-3 regions of the  HCV 
genome. The  use of   peptide, when a ppropriate,  eliminates  those  amino  acid 
sequences that are a source of  non-specific cross reactivity with other  antigens, 
and  significantly reduce the number of intermediate RIBA result (248). 
1.2.3.1.2.2. Western Blot Assay:  
The  use  of    immune  blot   technology,   also  known  as   the   Western   blot 
assay. This technology has  been rapidly expanding  area of  molecular  biology, 
especially    when   coupled  to  the  technology  of  expression  of   recombinant 
proteins. Western  blot required the use of  specific protein  to  detect  a specific 
antibody. This antibody is usually detected when specific proteins blotted on to 
nitrocellulose    paper   to   separate   the   proteins    depending   on    molecular 
weight (249). The  advent of   the  six-histidine (6-his)  tag technology, in which 6 
 histidines  are  added  to  the  code of  the protein  being  expressed,  allows  for 
proteins  to  be easily   and   rapidly   purified   using   either   nickel   or   cobalt 
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column.This  technology  has  greatly  increased  the  efficiency of  the  targeted 
protein isolation  (250).  Normally,  the   result   is considered positive  if  there  is 
a reactivity  with  two or more bands, indeterminate with one band and  negative 
with  no  specific  reactivity. The  strips contain  appropriate controls, including 
two  controls; one control  for  reactivity  to  the  proteins  from  the  expression 
system  and  the  other  control  to estimate the intensity of reactivity. The latter 
allows  for  a qualitative  assessment of   the  amount of  HCV antibody present 
which can be reported as 1+ to 4+ (251). 
A reagent with nickel attached to  the horseradish peroxidase  (HRP)  detection 
system  has  been marketed for use with the Western blots to eliminate the need 
for anti serum. The nickel  HRP reagent  (HisProbe™ HRP) binds  to the  6-his 
tagged   protein   with   high   affinity  and   thus  can  be  used  in  western   blot 
analysis.  This   method   is   simple,  rapid,   takes   less   time,  and   has    high 
reproducibility and high specificity (250).            
1.2.3.2. Nucleic Acid Testing: 
The presence of  HCV antibodies in patients infected  with HCV has led to  the 
development of immune serological tests that are specific for  these  antibodies. 
These  serological tests  detects antibodies of  current  and/or prior  exposure to 
HCV  infection, but  cannot  discriminate  between  recent  and  past  infection. 
Alternatively, the  detection of  HCV RNA  by  nucleic  acid  tests (NATs) may 
provide   evidence  for   current   infection. Nucleic  acid  tests   (Table. 4)   are 
employed  to  detect HCV  viremia   prior  to  immunological  sero-conversion. 
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Table No 4: Characteristics of available Nucleic Acid Tests for Hepatitis C 
Virus (adapted from VanGuilder HD, et al. 2008) 
 
 
 
 
Assay 
 
Manufacturer 
 
Technique 
Lower limit of
detection 
(qualitative) 
Dynamic range 
of 
quantification 
 
Amplicor® H C V 
v2.0 
 
Roche Molecular 
System 
 
Manual RT‐PCR 50 IU/ml NA 
Cobas® 
Am p licor® H C V 
v2.0 
 
Roche Molecular 
System 
 
Semi‐automated 
RT‐PCR 50 IU/ml NA 
Versant ® H C V 
R N A Q u alitativ e 
A ssay 
 
Bayer  Health 
Care 
 
Manual TMA 10 IU/ml NA 
Amplicor HCV 
Monitor®v 2.0 
 
Roche Molecular 
System 
 
Manual RT‐PCR 600 IU/ml 600 ‐500,000 
IU/ml 
Cobas® 
Am p licor H C V 
M onitor v 2.0 
 
Roche Molecular 
System 
 
Semi‐automated 
RT‐PCR 600 IU/ml 
600 ‐   500.000 
IU/ml 
LCx HCV RNA 
Quantitative 
Assay 
Abbott 
Diagnostic 
 
Semi‐automated 
RT‐PCR 25 IU/ml 
25 – 2,630,000 
IU/ml 
 
Versant® H C V 
R N A 3.0 A ssay 
Bayer  Health 
Care 
 
Semi‐automated 
b DNA 615 IU/ml 
615 – 7,700,000 
IU/ml 
 
Cobas® T aq M an 
HC V  T est 
Roche Molecular 
System 
 
Semi‐ automated 
Real‐time PCR 15 IU/ml 
43 – 69,000,000 
IU/ml 
 
Abbott 
Real Time 
 
Abbott 
Diagnostic 
 
Semi –automated
Real‐time PCR 12 or 30 IU/ml 
12‐ 100,000,000 
IU/ml 
 
Ultra‐Qual 
Qualitative  test 
 
National Genetics 
Institute 
 
RT‐PCR 40 IU/ml NA 
 
Super‐Quant 
Quantitative test 
 
National Genetics 
Institute 
 
RT‐PCR 40 IU/ml 40‐2,000,000 
IU/ml 
 
Quantiplex 
bDNA v3.0 
 
National Genetics 
Institute 
 
RT‐PCR 10 IU/ml 10 ‐ 100 million 
IU/ml 
 
 
N A= Not Available 
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 Since   NATs can   detect  HCV RNA  independent  of   immune  status  of  the 
patients,  are  valuable  in   detecting  HCV  RNA   in   immune    compromised 
patients (252).  These methods directly detect the presence of HCV RNA using a 
combination  of  amplification  and  detection  techniques. NATs  are classified 
into  qualitative  tests  (polymerase chain  reaction  and  transcription  mediated 
amplification),   and   quantitative  tests   (branched-chain  DNA  amplification, 
quantitative and real time PCR) (253,254,255). 
In  general, NATs  are  highly  sensitive  and   specific. A negative NAT  result 
following a positive  serological test  result  is  usually indicative of  a resolved 
infection,  however,  intermediate  or  low-level   viremia   may   occur   during 
chronic   infection. Clinicians  should  perform  a second NAT  6 or 12  months 
later  to  validate  NAT  results.  A positive  HCV NAT  result  indicates  active 
infection    regardless   of   antibody   test    result.  In   acute   infection,  as   in 
occupational   exposure,   the   NATs   result   will becom positive within 1 to 3 
weeks, i.e. several weeks earlier than serological tests (251).  
1.2.3.2.1. Qualitative NATs:  
Alberti   and   colleagues demonstrated that detection of HCV RNA in patient’s 
serum  is  the definitive marker of  hepatitis C liver disease regardless of serum 
ALT  levels. Thus, the documentation of  HCV viremia is  a hallmark  of  HCV 
diagnostics  in   anti-HCV  antibody  positive  and  in HCV   antibody-negative 
patients  with unexplained ALT elevations or liver disease documented by liver 
biopsy (256).  
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Qualitative NATs are used to confirm viremia, especially low level viremia  and 
in the future for screening blood donations, thus, testing of  blood donations  for 
HCV  RNA  dramatically  reduce  the  incidence  of  post  transfusion   hepatitis 
C (257). These techniques also have clinical important role in predicting   patients 
at risk for virological relapse once therapy stops  and  in  acute  HCV  (258,259,260). 
1.2.3.2.2. Quantitative Tests: 
Quantitative tests were used  to  assess  the  rate of  virological  response  which 
is important parameter to monitor  antiviral  therapy during treatment of chronic 
infection. Early  clinical  trials  showed  that  patients  with baseline  HCV RNA 
level   of  more   than  2x106copies/ml   had  a 9%   lower  sustained  virological 
response rate than those with less than 2 x106 copies/ml (261).  
Using  WHO  international   standard,  it   was   determined   that    8x105 IU/ml 
correspond  to  2 x106  copies/ml, therefore, by  extrapolation  of   these  finding 
high  viral  load  is  considered greater than  8 x105 IU/ml  (261)     
1.2.3.2.3. Polymerase Chain Reaction (PCR):      
The  most  common  assay used is polymerase chain reaction (PCR)  which  was 
discovered by Kary Mullis 1983 (262).  This relatively new technology relies  on 
amplification of a target piece of the viral genome to allow for easier  detection. 
The  viral  RNA  must first  be  converted in vitro  to  DNA by the viral  reverse 
transcriptase  enzyme. As  for  RT-PCR, the  RT  step converts  RNA to  cDNA, 
which  is  used  as a template for  the PCR.  Primers  in  which  the  5` UTR  are 
commonly used because this is  the most conserved region of  the  genome  (263). 
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Qualitative RT-PCR was developed by Roche (HCV AMPLICOR v2.0), which 
include  37  amplification cycles followed by hybridization to an HCV-specific 
oligonucleotide   probe.   This   technique  is     a remarkable   advancement   in 
molecular   diagnosis.  The   semi   automation  of   PCR   using   the   COBAS 
AMPLICOR® instrument is  where both  the thermal   cycling   and   detection 
steps  are performed automatically. This development is  another  forward  step 
that further reduces labor contamination risk, and time (264).  
Molecular techniques based on  RT-PCR are  also valuable in  measuring  viral 
load.  The  qualitative  test    has  lower  limit  of   detection  of   50 IU/ml   and 
sensitivity of  96%  and  specificity  more  than  99%   (265).  HCV RNA can  be 
quantified by  means  of   target amplification technique used competitive PCR. 
These   standardized  assays   are   commercially   available;   Amplicor    HCV 
Monitor® v2.0 and  its semi-automated version Cobas® Amplicor v2.0 (Roche 
Molecular Systems) with  a detection  limit  of   600  IU/ml, and   LCX®  HCV 
 RNA   Quantitative  Assay   (Abbott    Diagnostics)  with   detection  limit    of 
25 IU/ml (266).  
National  Genetics  Institute  has  a reference  laboratory  qualitative  PCR   test 
known as Ultra-Qual, with a sensitivity of  more than 96%, specificity of  more 
than   99%   and   detection  limit   of   40 IU/ml  (267).  A quantitative test  from 
National   Genetics   Institute   is     a Super-Quant   with   detection   limit    of 
4o IU/ml (268).    
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1.2.3.2.3.1. Real Time PCR:      
In  molecular biology Real Time PCR  also  called quantitative  real  time  PCR 
(Q-PCR /qPCR),  is  a laboratory  technique based  on PCR,  which is  used   for 
amplification, quantification and detection of one or more specific sequences in 
a DNA  sample (269).  Abbreviations  used  for  Real Time  PCR   methods  vary 
widely   and  include   RTQ-PCR, Q-PCR  or   qPCR (247).  Real-Time  reverse-
transcription   PCR  is  often   denoted   as   qRT-PCR,  RRT-PCR(270),  or    RT-
rtPCR (271).  The  acronym  RT-PCR  commonly  denotes    reverse-transcription 
PCR and not real-time PCR, but not all authors adhere  to  this  convention  (272). 
The  procedure follows  the  general principle  of   PCR,    reverse-transcription 
qPCR  (RT-qPCR)  was  initially  developed  as a technique to  amplify  nucleic 
acid  sequences  to  allow  for  detection  and  relative  quantification   of   target 
RNAs (273) . Real-time reactions are  carried out in a thermo-cycler that   permits 
measurement  of   a fluorescent   detector    molecule,  which    decreases    post-
processing  steps  and   minimizes   experimental  errors (274).  This  is  the  most 
commonly achieved through the use of fluorescent based technology  including: 
(1)  probe   sequences   that    fluoresce  upon    hydrolysis   (TaqMan)  (275)    or 
hybridization  (LightCycler) (276), (2)  fluorescent   hairpins  (The LUX)   (277),  or 
(3)  intercalating   dyes  (SYBR Green) (278).  
TaqMan   chemistry   uses    the   5`-3`   exonuclease    activity   of    Taq   DNA 
polymerase,   which    degrades   a non-extendable    fluorescent    DNA    probe 
following  hybridization and  extension in the PCR. Sequence-specific  TagMan 
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probes  are  labeled  with both DNA fluorescent reporter and a quencher, which 
are   maintained  in  close  proximity until hybridization to the target occurs.  In 
conventional   TaqMan  technology, the  reporter fluorophore   and  fluorescent 
quencher   are   bound  to  the  5`  and  3`  ends   of   the  probe   sequence,  and 
fluorescence-resonance   energy   transfer   (FRET)   from   the  reporter  to  the 
quencher achieves suppression of the reporter molecule fluorescence (279). 
Following annealing of the forward and reverse primers to the target  sequence, 
the  TaqMan  probe is designed  to  anneal between these  primers  sites  and  is 
 hydrolyzed by the 5`-3` exonuclease activity of Taq polymerase. If  no product 
is  present, the  probe  does  not   bind and  is not  degraded, hence  the reporter 
remains quenched. Hydrolysis of  the  probe  results  in   desuppression  of   the 
reporter  and  a subsequent cumulative increase in fluorescence proportional  to 
the amount of  transcript  present.  This oligonucleotide primer/probe  approach 
increases  accuracy  and   specificity  of    PCR    product  detection due  to  the 
requirement for  precise, matching of  three independent  nucleotide  sequences 
(gene-specific) (275).  Using a different fluorophore on each gene-specific probe, 
reactions    can   be    multiplexed   to    quantify   multiple  genes   in    a single 
reaction (280, 281).       
HCV   RNA  quantitative assay  based  on  Real Time PCR   amplification  like 
Cobas® TaqMan HCV Test with detection limit 15 IU/ml, can be coupled with 
an automated  extraction  procedure  in  Cobas Ampliprep ®, and  Abbott  Real 
Time™ HCV assay. This  assay uses  the  Abbott  m2000 system and   also can 
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be  coupled  with  an automated extraction procedure with detection limit of 12 
or 30 IU/ml  (282).  
1.2.3.2.3.2. Transcription mediated Amplification: 
Transcription  mediated  amplification  (TMA)  involves  more complex  set  of 
reactions  with  T7  RNA polymerase  and  RT  under  isothermal conditions  to 
form  detectable  levels  of  RNA. This  type  of amplification uses primers that 
contain  T7 RNA  polymerase binding sites so that  RT synthesizes cDNA  that 
becomes a template  from which T7 RNA polymerase can synthesize numerous 
copies  of  RNA. The RNA amplicons reenter   the  TMA  cycle   and   become 
templates  for  the next  replication  cycle (252).   The  TMA-based VERSANT® 
HCV RNA  qualitative  assay  is  able to detect very low  levels of  HCV  RNA 
(5-10 IU/ ml)  that  are  undetectable with  RT-PCR systems with  sensitivity of 
more  than  98%, but  it is not approved by FDA  (283). The Procleix HCV assay 
also  uses TMA  technology  approved by  FDA  in  2002  for  the  screening of 
HCV in  blood donations which are antibody negative (284). 
 1.2.3.2.4. The branched-chain DNA Amplification: 
The  bDNA technology which  is used  for  the  detection of  nucleic acid target 
molecules is  a sensitive and reliable tool  in the diagnosis of viral and bacterial 
infections and for monitoring disease progression during the course of  therapy. 
More  recent  efforts  have been focused on  the development of  bDNA  assays 
for quantification of  HCV RNA  (285, 286).  The bDNA assay achieved by signal 
amplification on the  bDNA probe after direct binding of  a large  hybridization 
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complex to the target sequence (287,288). This series of hybridization steps results 
in a sandwich complex of probes and target  sequence. These unusual synthetic 
oligonucleotides are composed of a primary and secondary sequence that result 
in  a branched  structure  extending  from the primary sequence (289).  
In the most recent third-generation bDNA assays, target-specifi oligonucleotide 
form   (label   extenders and  capture extenders)  then  are hybridized with  high 
stringency  to  the  target   nucleic   acid. Capture   extenders  are   designed   to 
hybridize to  the target  and to  capture  probes, which  are  attached to a micro-
well plate. Label extenders are designed to  hybridize t o contiguous regions on 
the  target and to provide sequences for hybridization of   a preamplifier  oligo-
nucleotide. Signal amplification begins  with  preamplifier   probes hybridizing 
to label extender. The pre-amplifier forms stable hybrid only if  it hybridizes to 
2 adjacent  label  extender.  Other  regions  on  the  amplifier  molecules  create 
 a branched  structure.  Finally,  Alkaline Phosphatase-labeled  oligonucleotide, 
which  are  complementary to bDNA  amplifier  sequences bind  to  the  bDNA 
molecule by  hybridization. The bDNA signal is a chemiluminescent product of 
the    Alkaline    Phosphatase   reaction. The   signal  in   the   bDNA   assay   is 
proportional   to   the  number  of   Alkaline   phosphatase-labeled   probes  that 
hybridized to bDNA secondary sequences (288). 
Accurate,   reproducible  first-generation   bDNA   assays  were developed   for 
detection of HCV RNA  in human plasma  (Quantiplex  HCV  RNA 1.0  assay) 
with a dynamic quantification range in  human plasma from  3.5 x 105  to  1.2 x 
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108   HCV RNA copies/ ml  (285,290). When compared with  HCV, RT-PCR  that 
showed   greater  sensitivity with  lower  limit  of  detection 2.4  x  104,   bDNA 
had  a greater reproducibility and less time consumption than RT-PCR test (291). 
A second  generation  of  Quantiplex  HCV  RNA 2.0  assay  was  developed to 
reduce the variation in detection rate among HCV genotypes, with  lower  limit 
of detection 2.0 x 105 versus 3.5 x 105  (HCV RNA 1.0 Assay) (290).  
Third generation  bDNA  technology  form  is  a Versant® bDNA 3.0 Assay. It 
uses   isoC   and   isoG-substituted   oligonucleotides   to   reduce   non-specific 
hybridization,  and  increase  sensitivity  approximately  62-fold  292).  It  has   a 
lower    limit  of    3.2  x  103  copies/ml (615 IU/ml)  and  upper  range  of   4 x 
107copies/ ml  (7.7 x 106  IU /ml).  It is  highly  reproducible  with  a specificity 
ranges from 96% to 98.8% (292).  
1.2.3.3. Genotyping and serotype tests:   
Genotype tests  are  important  clinically  as  they  predict  most  accurately  the 
treatment,  that   should   be  systematically  determined   before   initiation    of 
therapy. This  is  because they  are  essential  in determining the  indication, the 
duration  of   treatment,  the  dose (of   interferon   and   ribavirin),   virological 
monitoring procedure. In addition, they are used to assess the end of  treatment, 
importantly  the  sustained  virological  response (the end point of therapy) (293). 
The  HCV  viral  genotype  can be determined in different forms. There are two 
methods of  assays for  the diagnosis of  HCV  viral  type, serotype  and   geno- 
 type (293).   
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1.2.3.3.1. Serotype: 
Serological    tests    include    various    methodologies,  but    mainly    ELISA 
methodology is currently employed. They detect  the specific  antibodies to  the 
six HCV genotypes in the NS4  region of  the genome. The advantages of these 
tests  is   that  they  are  suitable  for  large   epidemiological  studies. They  are 
simple and  have low  risk  of contamination, but  their  main disadvantages are 
that they cannot determine  the quantity of circulating viral particles, have lower 
sensitivity and  specificity in the diagnosis of HCV genotype. Genotyping  tests 
performance is limited in the evaluation of  immune compromised patients (294).  
An accurate and specific ELISA for the detection  and  quantification  of  HCV 
core  antigen (Total  HCV Core Ag assay)  has  recently  been  developed. This 
assay  has a higher  sensitivity  than   the  earlier  version because  the  immune 
complex  dissociation  step  prior  to   antigen   detection  was  omitted  by   the 
incorporation of   monoclonal  antibodies, thus, their  lower  limit  of  detection 
(2x104IU/l) is significantly higher (295).  
1.2.3.3.2. Genotype tests:        
Genotype is  the  most  direct  method  that  differentiates  HCV  genotypes and 
subtypes.These techniques include: direct sequencing and reverse hybridization 
technology   with   genotype-specific  probes  and   PCR.  Genotyping   can   be 
determined  by  sequencing  PCR  products  with a commercially  available line 
probe assay (LiPA) .This methods  uses  PCR  products  from  the 5` UTR   that 
hybridize  to  type-specific   probe  embedded on  nitrocellulose  strip (296).  The 
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first-generation   line-probe  assay, used  only  sequences from  the  5`UTR  for 
genotyping.  Because  the 5` UTR  is  conserved,  it  provides  a relatively   low 
discrimination  power   for   genotypes   and   subtypes. The  5` UTR   contains 
multiple  genotype-specific sequences  distributed  over  small variable regions. 
They  provide  accurate  genotyping  information  for  genotypes 1 to 5 and  for 
genotype 6 subtypes a and b; however, owing to  high sequence similarity, sub-
type c to 1 of genotype 6 cannot be  distinguished from  genotype 1 by analysis 
of the 5` UTR  alone, also, the accuracy of differentiating subtypes 1a and 1b is 
limited by 5` UTR  analysis (297). Therefore, second-generation line-probe assay 
(The LiPA 2.0)  was  developed by  using  sequences from  the  core  region  in 
addition  to  the 5` UTR to identify genotype 6, subtypes c to 1, and to improve 
the  accuracy of  the identification of  subtypes 1a and 1b. Comparing the LiPA 
2.0  assay with  sequence analysis, the LiPA 2.0 assay was able to identify 96% 
of the genotypes and subtypes (298).   
Direct  sequencing is  an ideal  and  definitive  method  for  the  study   of  viral 
genetic variability and gives the most complete information on the variations of 
the  sequences  analyzed by  using  direct  sequencing  analysis  of  the  5`UTR. 
Trugene® HCV 5`NC genotyping kit  assay based on  direct sequencing of  the 
5`UTR, but  the  accuracy of  subtypes is  poor because it depend on the 5`UTR 
only .Currently  the  Trugene™  NS5B  HCV  genotyping   assay,  additionally 
analyses the NSB region under development (299).  
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Genotyping based on  real-time  PCR  technology is  less  time consuming than 
direct  sequencing. Preliminary  data  revealed a 96%  concordance at the geno-
type level and a 93% concordance on genotype 1 subtype level when compared 
with  direct  sequencing of  the  NS5B and 5`UTR regions. Nevertheless, single 
genotype  2,  3,  4,  and  6  isolates  were  misclassified at  the  genotype   level, 
indicating a need for assay optimization (300).  
1.2.4. Routes of Transmission and Prevention: 
HCV infection  is classified as a community-acquired disease, the  predominant 
route of   transmission of hepatitis C virus is always changing. 
1.2.4.1.Direct percutanous exposure: 
Direct percutanous exposure such as transfusion of  contaminated blood,  blood 
products and body tissue is classified  as  a high  risk group for  transmission of 
HCV.  By  1990,   the   risk   of   transfusion-associated  HCV   infection    was 
approximately1.5 % /recipient or  approximately  0.02% /unit transfused due to 
implementation of  new  tests  that  reduces further  the  risk  for  infection (301). 
Patients  with   hemophilia  who   were  treated   with   blood   products,  before 
inactivation  of   these  products  have  high  rates  of   HCV   infection   (90%). 
 Since  1994  all  immunoglobulin  products   undergo  inactivation   procedure, 
therefore   the   positivity among   chronic  hemophilic   patients decreased (302). 
Prevention  of  HCV  transmission  from blood transfusion, blood products and 
body tissue transplant is achieved by excluding blood, plasma, organ and tissue 
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from donor with risk factors for blood borne viral infections or with serological 
markers for HCV infection (303). 
1.2.4.2. Sharing equipment: 
Intravenous  drug  users  are  a high-risk  group  for   transmission  of  infection 
through transfer of  HCV-infected blood by sharing syringes and needles either  
directly  or   through   contamination  during    preparation  of  equipment  (304).  
However, HCV  infection  is  acquired  more  rapidly  than  other  blood-borne 
viruses when the infection is initiated through contaminated needles (305).  HCV 
infection can be prevented by using sterile  needles and  syringes and  avoiding 
blood contact during injection and withdrawing blood (306).  
1.2.4.3. Skin penetration by sharp objects: 
Skin  penetration  by  sharp  objects (tattooing,  ear  piercing  and  acupuncture) 
have  been  considered  as a transmission  risk  for  HCV  infection,  because  it 
involves penetration of epithelium and bleeding (307). Only 1% to3% worldwide 
reported  a history of  tattooing and ear piercing (308). Professional tattooists and 
services   offering   body   or  ear   piercing   should  follow   infection   control 
guidelines  and  standard  precautions  to  prevent the infection (washing hands, 
using latex gloves, and cleaning and disinfecting surfaces) (309). 
1.2.4.4. Transmission between health care workers: 
The   risk   of   HCV  transmission   among   health    care    workers,    through 
percutaneous exposure such as needle stick injury or splashing of contaminated 
fluids  from  infected  patients,  is  associated with  patients  reactive  for  HCV 
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RNA (310).  However,  the  prevalence of  HCV   infection   among   health-care 
workers ranges between 1%-2% (311). Persons at  risk of  occupational exposure 
to  HCV should adhere to standard barrier precautions and engineering controls 
should  be   implemented   to  prevent   exposure  to   infected  blood   or   body 
fluids (312). 
1.2.4.5. Sexual transmission: 
Prevalence of  HCV infections transmitted sexually was lower than that of other 
viral sexually-transmitted diseases (STDs) such as Hepatitis B virus or  Human 
Immunodeficiency virus (HIV) (313).  HCV  virus was  detected in  semen  from 
men  and  in menstrual blood from women, thus sexual transmission cannot  be 
dismissed as a possible route of  transmission (314). It  has been noted  that  15% 
-20%  of  patients with  acute HCV  infection  who  have been reported to CDC 
sentinel counties surveillance system have  a history of  sexual exposure in  the 
absence of other risk factors (305).  
Other studies reported transmission of  HCV among  patients who  attend  STD 
clinics, and  denied percutaneous risk  factors, among their steady partners. The 
prevalence of  HCV infection among male patients with  an anti-HCV  positive 
female  partner (7%)  was  similar to that  among  male patients with a negative 
female   partner   (8%).  However,  female   patients  with   anti-HCV   positive 
partners were almost  fourfold  more likely to have HCV infection than females 
 with    a negative  male   partner   (10%  versus  3%,  respectively). These data 
indicated that sexual transmission of HCV from male to  female might be more 
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efficient than from  female  to  male (315).  The  risk  of  sexual  transmission  of  
HCV  is low unless there  is  blood  contact during  intercourse,  thus, the  safe  
sex advice should include avoidance of intercourse if  there is ulceration in the  
genital tract  or during menstruation  (316). 
1.2.4.6. Mother-to-child transmission: 
HCV  transmission  occurs  in  approximately  3%  to  7%  of  infants  born   to 
mothers  with  active  HCV   infection;  50%  of   those  infants   resolve   HCV 
infection. A significant number of  infected children resolve  HCV infection by 
the  age of  2 years  without  intervention (317).  Anti HCV  positive mother may 
transmit  the  virus  to  their  offspring  during  gestation  or  delivery. Infection 
may  occur  through  maternal  blood, which  contains free  HCV  particles  and 
occasionally HCV-infected cells as well (318).  
The risk of  transmission increases during vaginal  delivery if  the mother  is co-
infected with  HIV. High maternal viraemia leads to the presence of HCV RNA 
in breast milk (319). Guidelines  from the American Academy  of  Pediatrics, the 
Centers for Disease Control and Prevention  (CDC), and  the American College 
of  Obstetricians and Gynecologists  (ACOG)  don’t prohibit  breast feeding  in 
infants of  HCV-positive mothers, but  it is  advisable to suspend breast feeding 
if  there are cracked  nipples  (320). The  data regarding  the relationship between 
delivery  mode  and  HCV  transmission are limited, which indicates that  there 
are  no  difference  in   transmission between  infants  delivered   vaginally  and 
infants delivered by caesarean section (321). 
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1.2.4.7. Household transmission: 
Person  to  person   transmission  in  the  household  setting  appears  to  be  un- 
common, and  household infection  other  than  via  percutaneous blood contact 
has  not  shown to be  epidemiologically important in the transmission of  HCV 
infection. The  reported  prevalence of  anti HCV due to household contact was 
4% (322). Nevertheless, the possibility of blood contact exists through sharing of 
tooth brushes, razors or other house- hold items (309).  
1.2.5. Treatment of HCV Infection:                                    
Antiviral  therapy  is  recommended for acute and  chronic  HCV infection. The 
short-term  aims of  antiviral  therapy  are  to  stop viral replication, limiting the 
infectivity, reduce liver cell inflammation and necrosis, thus the  progression to 
fibrosis  doesn't  occur. The  major long-term objective  is  to   prolong   patient 
survival  by decreasing the incidence of cirrhosis, liver failure and HCC. In  the 
majority  of cases the total eradication of  the virus was not achieved. However, 
therapy  may   reduce   the  risk  of   acute  cases from  becoming  chronic   and 
suppress  the  disease  progression from  chronic  active  hepatitis  to  cirrhosis, 
reducing the risk of  HCC (323).  
Interferons   are  naturally occurring  antiviral  proteins  that  act  by  the  direct 
inhibition of viral  growth   and replication and by stimulating the host immune 
response  against  virally  infected  cells. The  first reported use of recombinant 
alfa interferon  to  treat  HCV  infection  was in  1998 (324). Only  patients   with 
detectable  HCV RNA  should  be  considered  for  treatment. Current  standard 
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treatment for chronic hepatitis C is the combination of Pegylated interferon alfa 
and Ribavirin.  A response at the completion of a course of treatment is defined 
as an end of treatment  response (ETR), but  the efficacy end-point of  hepatitis 
C  treatment  is the sustained virological  response (SVR) which  defined as the 
absence of detectable HCV RNA in  serum with the lower limit of detection by 
PCR  6-12 months after the completion of treatment (325). 
The  decision to   treat  patients  with  chronic  infection  depends  on   multiple 
parameters, firstly, viral  factors such as  viral  load  (the  amount of circulating 
virus), genotyping  which  determine the  indication  and  duration of  treatment 
and  the dose of ribavirin  and  virological monitoring procedure. Secondly host 
related factors that include alcohol consumption, age at acquisition of infection, 
obesity and the patients  willingness  to  be  treated. Thirdly, the disease related 
factors such as the precise assessment of severity of liver disease, the degree of 
fibrosis,   and   the   presence  of    absolute  or   relative   contraindication   to 
therapy (326).  
The efficacy of  these therapies is  extremely poor, and the post therapy relapse 
rate is very high, such that sustained biochemical  response is  observed in  less 
than   20%  of  the  patients  (327),  consequently, there  is  an  urgent   need   for  
development of  novel  therapeutics. The  antiviral effects of  INF results  from  
both  modulation of  the immune  response to  viral  epitope  and  inhibition  of  
viral replication (328,329) 
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The major  initial effect  of  interferon-α is to block virion production or release 
but the subsequent second-phase decline  is believed to  reflect the death rate of 
productively  infected  cells,  in which  HCV-specific cytotoxic  T-cell  activity 
 could  be  a major contributor  (330). 
The mechanism of  synergism  provided  by  ribavirin  is also unknown, but  its 
benefit  has been clearly achieved, the 5`triphosphate metabolite of  ribavirin is 
believed to act as inhibitor of  the  RNA-dependant RNA  polymerase  (RdRp).  
However,  two other  mechanisms of  antiviral actions of  ribavirin  have  been 
proposed, first inhibition of the inosine-monophosphate dehydrogenase enzyme 
after  phsophorelation of  ribavirin  to  ribavirin-5`  triphosphate and  that   may 
deplete  intracellular  pools  of  guanosine  triphosphate The second mechanism 
is  that  ribavirin  inhibits the quanylyltransferase  by  ribavirin-5`-triphosphate, 
which  could interfere  with  translation  of  cellular and viral RNA (331).           
The approved dose of  pegylated INF  alfa-2a  is 180 µg per week, independent 
of  body weight, whereas that of  pegylated  INF alfa-2b  is  weight  adjusted at 
1.5  µg/kg  per  week,  which  is   identical  for  all   HCV  genotypes .  Patients 
infected  with  HCV  genotype 1 should  receive a high dose of  ribavirin  about 
1000  to 1200 mg   daily based  on   body   weight   less  than  or   greater   than 
75kg (325),  However, monitoring of  HCV  RNA  load  decrease during  therapy 
is recommended in  order  to  avoid  treating for  patients with no  likelihood of 
sustained virological  response ( SVR )  unnecessarily (332).  In  this  case, HCV 
RNA quantification should be performed at the base line and  after 12 weeks of 
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treatment. Both measures must be performed with the same technique to insure 
comparability of  the results  at  the  two time levels (325). 
Treatment must be continued when the base line HCV RNA level is divided by 
100 or more, or when  HCV RNA  is  undetectable at week 24. If HCV RNA is 
undetectable at week 24, treatment must be continued until week 48, with  high 
likelihood of  an SVR. In  contrast. If  HCV  RNA  is  still  detectable  at  week 
24, the likelihood  of  an  SVR  is virtually none  and  treatment can be stopped 
or continued aiming at slow liver disease  progression  in   patients  with severe 
prognosis, but with no possibly to  resolve the  infection.  HCV RNA  detection 
at  the  end of  therapy is  highly predictive of a post-treatment relapse, whereas 
the  absence  of   HCV  RNA  at  the  end  of  treatment  indicates  a virological 
response (332). 
The  therapeutic  treatment of   HCV genotype 4, 5  and  6 is similar  to  that  of 
HCV  genotype  1,  but  for   a total  of  48  weeks   using  the   same  dose,  the 
virological  response  must  be  assessed  at  the  end  of  therapy and  24 weeks 
later (236).  HCV genotype 2  and  3  show  70% - 80% SVR  with a low dose  of 
ribavirin   and   only 24  weeks  of  treatment (293).  The  recommended  dose  of 
pegylated  INF  alfa-2a or alfa-2b is the same as HCV genotype 1 (180µg/week 
or 1.5µg/kg  per week respectively) and a fixed dose of ribavirin is 800 mg/per 
/day.  No  monitoring  of   HCV RNA  level  or   changes  during   therapy   are 
recommended  in  patients  with  genotype  2  or  3  infection,  because  the vast 
majority  of  them  become  HCV  RNA-negative  early  during  treatment. The 
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virological response must be assessed at the end of therapy, and 2 4 weeks later 
in order to determine whether the virological response is sustained (236).  
Several   recent  studies   have  challenged  the  conclusion  that  HCV  is  truly 
eradicated  after   a documented  sustained  virological  response. In  one  study 
researchers detected HCV RNA in 15 of 17 serum samples and 9 of 12 samples 
of peripheral blood mono-nuclear cells taken from patients previously  reported 
negative  for  HCV   RNA   after   either   spontaneous   or    treatment-induced 
resolution (333).  A second  research  group  reported  detection  of   HCV  RNA 
frequently in liver biopsy and peripheral blood mononuclear cells from patients 
with  abnormal  liver  function tests  whose  serum  sample  tested  negative for 
HCV  antibody  and   RNA, which   means  that  Occult  HCV   infection   may 
occur  (334).   
New classes of  promising  medication  are  under development, putative   anti-
fibrotic medications such as interferon gamma are undergoing evaluation. RNA 
polymerase, helicase, and protease inhibitors are in early phase trial (335).            
1.2.5.1 Adverse effect and contraindications: 
Adverse effects of  pegylated interferon alfa  are numerous and the incidence is 
high.These effects include: fatigue, fever, headache, myalgias, insomnia, chills, 
nausea,  anorexia, weight  loss,  irritability,  depression, injection  site  reaction, 
neutronpenia, thrombocytopenia  atpica, and  autoimmune disease exacerbation 
(hypo and hyperthyroid, eczema and psoriasis). While ribavirin  adverse effects 
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include:  rash,  loss  of   weight,  shortness of   breathing,  nausea,  occasionally 
hemolytic anemia, anorexia teratogencity  and cough (293). 
1.2.5.2 Contraindication to treatment:  
Contraindication to treatment  include decompensated liver disease, pregnancy, 
active   autoimmune  disease,  severe  psychiatric   disease,  hemolytic  anemia, 
poorly  controlled  diabetes   mellitus,  uncontrolled  medical disease,  seizures, 
 coronary   artery   disease, chronic   obstructive  pulmonary  disease  and  heart 
failure (4). 
1.2.5.3 HCV Vaccine:   
The genetic heterogeneity of  HCV is  likely to make the development of  HCV 
vaccine   difficult.  A vaccine  that  is  consisted  of   recombinant  E1  and   E2 
proteins   of    HCV (genotype  1a)   was   tested   in    chimpanzees.  Of   seven 
chimpanzees  that  were challenged  with  HCV-1  after  vaccination, five  were 
protected against reinfection, compared with none of four control unvaccinated 
chimpanzees. The  finding  that   these  proteins   derived   from   hypervariable 
regions of  HCV genome, can elicit protective immunity poses major challenge 
for  the  development  of  a broadly  effective  vaccine  for  the   prevention   of 
HCV (336).  
1.2.6. HCV during Pregnancy  
During   pregnancy   there  is  an  increased  production  of  hormones  that  has 
immune     suppressive     properties.   These     hormones     include      adrenal 
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corticosteroids,  estrogen,  and   progesterone.  After  delivery  these  hormones 
decrease  rapidly  and   the effect of  immune  suppression is lost (337).  
Some  studies noted  that the rate of  progression of  inflammation  and fibrosis 
was significantly higher during pregnancy, but  in most cases these changes are 
reversible  (338).  The  improvement  in  serum  ALT  levels  may  be caused  by 
physiologic   changes   during   pregnancy,   including   changes   in     immune 
reactivity,  expansion in  plasma  volume,  and  high  plasma  concentrations of 
estrogen (339).   
During  pregnancy,  serum  HCV  RNA  concentration were noted to be  highly 
variable.    In  some   women   HCV   RNA   levels   rise   toward    the  end   of 
pregnancy (340,341, 342).  The   rise  appears to be  in the order of  50% above base 
line.  However,  few  patients  in  one study  were found  to  have  undetectable 
serum   HCV RNA  during  pregnancy, and  become  positive  for   HCV  RNA 
again  in  the  postpartum  period (343). In  another small study HCV RNA levels 
fluctuated  during  pregnancy  and  become lower  or  undetectable  in the post-
partum period. Elevation  in  viral  levels are a risk  factor for  mother-to-infant  
transmission, and   these   levels  should  be   measured  in  the  third  trimester 
because the  measured concentrations of  HCV RNA at t he onset of pregnancy 
may  neither  be  representative nor predictive of  the HCV RNA  concentration 
at  the  time of delivery (344). 
Conversely, chronic HCV  infection does not  appear to have an adverse  effect 
on  the course  of   pregnancy or  the  weight  of  the new born   infant. The rate 
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of   spontaneous   abortion  was   approximately  the   same  as  in   the   normal 
populations (345, 346). Many  infants of  mothers  chronically infected with  HCV 
are found to have detectable anti-HCV in their blood, which they have acquired 
through    passive   transplacental   transfer   of   IgG-antibody.  This   passively 
acquired  antibody continues to be detectable in the infants  for  the  first  12  to 
15  months  after  delivery,  occasionally, and as  long  as  3 months  later.  The 
possible criteria for a more rigorous definition of mother-to-infant transmission 
of  HCV  include (1) detectable  anti-HCV in  an infant  who  is  more  than  18 
months old, (2) detection  of  HCV RNA in  infants who are 3 to 6 months  old, 
(3)  detection of  HCV RNA  in  infants  on  at  least  2  occasions,  (4)   finding 
elevated serum  aminotransferase levels in children or  (5)  confirming identical 
genotype between mother and child (347). 
The rate  of  mother-to-infant  HCV  transmission is  critical  in  predicting  the 
burden  of  HCV infection  in  future  generations. Geographic  variations  were 
apparent from studies in which the  rate  of   mother to  infant transmission was 
detected, if the mother was known to be  anti-HCV positive only,  the weighted 
rate  of transmission was 1.7% (compared with a crude rate of number positive/ 
number at  risk of  5.6%). If the mother was known to be viremic, the weighted 
rate of  transmission was  4.3%  (crude rate 8.1%) (348).  HCV co-infection with 
HIV  greatly increased  the rate  of  transmission  rate to 19.4%  compared with 
 3.5%   for HIV-negative mothers (349).  
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1.2.6.1. Factors correlating with mother-to-infant transmission of HCV: 
 1.2.6.1.1. Viral levels 
Numerous studies  indicated  that  the higher  the concentration of  serum HCV 
RNA  the  more likely  is   mother-to-infant   transmission. In   general,  studies 
showing  correlation  of  HCV transmission  with  maternal viral load exhibited 
the effect at 105 to 106 copies/ml. Differences in the  stage of  pregnancy during 
which   maternal  viral  levels  were  tested may explain some of the conflicting 
observations on this point (348).  
1.2.6.1.2. HIV Co-infection 
Co-infection  with  HIV has been greatly associated with transmission of  HCV 
to  the  newborn  infant (350,351).  Based  on 8  studies that  included data on both 
HIV-positive  and HIV-negative women, the crude rate of  the mother-to-infant 
transmission was  22.1% and 4.3%  respectively. The weighted rate of  mother-
to-infant transmission was 19.4% and 3.5%, respectively (351). 
1.2.6.1.3. Intravenous drug use (IVDU) 
Intravenous  drug  use (IVDU)  correlates  with  an increased risk of mother-to 
infant transmission. Studies of   mother-to-infant   transmission  among  IVDU 
showed   high   prevalence  (the  crude  rate   was   10.8%    and  weighted  rate 
was 8.6%)  (352).  
1.2.6.1.4. HCV genotype. 
Maternal-infant-transmission  occurs  with  all   known   genotypes. To date, no 
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 obvious  correlation  between  HCV genotype   and   rate   of   mother-to-infant 
transmission of HCV has been reported (353). 
1.2.6.1.5. Disease activity 
There  have  been   few  observations relating  to disease activity in the  mother 
and  the  likelihood   of transmission of HCV infection to the infant. In general, 
hepatic  inflammation  appears to  be  reduced during  pregnancy,  as shown by 
a decrease in  serum ALT  levels in third  trimester. One   report has shown that 
mother-to-infant   transmission correlates  with  peripheral  blood  mononuclear 
cell infection by HCV (354)  
1.2.6.1.6. Complication of Delivery 
Chronic HCV infected women may be at  risk  for complications of  pregnancy 
and  delivery for reasons independent of the HCV infection. Some observations 
suggest   that   prolonged  rupture  of   the   membrane  more   than   6  hours  is 
 associated with a higher  rate of  transmission of  HCV (355),  but  other  studies 
have not shown this association (356). 
1.2.6.1.7. Type of Delivery 
Some  studies suggest  that  mother-to-infant  transmission of  HCV infection is 
more likely  to  occur  with vaginal  delivery. Other studies do not  confirm this 
finding  (345).  Elective  cesarean   section   may   confer   some  protection,   but 
emergency  cesarean section does not (357).  For  vaginal delivery  and  cesarean 
section  respectively,  the  weighted  rate  of  mother-to-infant transmission was 
4.3%  and  3.0%  (crude rate 6.7% and 6.8% respectively) (317).   
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1.2.6.1.8. Invasive Procedure 
Some  evidence has shown  that  amniocentesis is a potential risk  for  spreading 
infection to  infant;  however, HCV RNA is  detected in  amniotic fluid  (358,359), 
and   this   finding   raises   the  possibility  of  in utero  infections.  Cord  blood 
positivity  for  HCV RNA is extremely difficult  to interpret as  an indication of 
in utero infection because minute contamination with maternal blood cannot be 
excluded (349).  The possible effect of  elective Cesarean section to diminish the 
risk of mother-to-infant transmission argues for infection at or around  the time 
of  vaginal  delivery (350,357).  Finding  HCV RNA in the  serum of  the newborn 
infant  in  the first few days of  life is consistent with infection occurring  either 
in-utero or at time of delivery (360).  
1.2.6.1.9. Breast feeding 
HCV  can  be  detected  in  breast  milk  or  colstrum (361).  Nevertheless,  breast 
feeding  is  generally  not  considered  to be a risk factor   for   mother-to-infant 
transmission of   HCV (362.363).  In published   studies, the rate of transmission is 
nearly  identical  in  breast  or  bottle-fed  infants. The safety of   breast feeding 
operates  on  the  assumption  that traumatized, cracked, or bleeding nipples are 
not present (317).    
1.2.6.2. Outcome of mother-to-infant hepatitis C infection in infants:              
The  outcome  of    mother-to-infant   hepatitis   C   virus     infection    requires 
clarification.  Some infants may have transient viremia  without  real  infection, 
other infants may have acute self-limited infection that is clinically unapparent. 
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Very early spontaneous resolution of mother-to-infant infection are compelling 
in      those    children    who    developed   biochemical   evidence  of    hepatic 
 clearance pontaneousS  .)364,365(  hepatitis C viremia oftime  at the inflammation
or  transient  viremia  was  described  in 17% of  all reported cases of mother-to 
-infant transmission (366).  
The  outcome of   most infants with chronic infection acquired through mother-
to-infant transmission appears to be mild,  and most of them are asymptomatic. 
Among  studies  describing  mother-to-infant transmission rates, liver histology 
was  described  in only 17  infants,  the  reported  age  at  time of   liver  biopsy 
ranged from 9 months to  5.5 years (367). The majority of liver biopsies revealed 
changes   consistent  with   chronic  hepatitis.  Fibrosis  on   liver   biopsy   was 
described in 3 cases (368). One  infant was  successfully  treated  with  interferon 
alfa (369). Three of the 17 infants died (370), 1 of these was co-infected with HIV, 
whereas another received 6 months of parenteral nutrition (371). 
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Chapter Two 
2. Materials and Methods 
 
 
 
 
2.1. Study design: 
The present study is a case control study. 
2.1.1. Study Area:  
This study  was  carried  out at  the  antenatal  clinics  in  Sabia-Gizan  (Alemies 
National  Hospital, Sabia  General  Hospital and  Primary Health  Care  Centers) 
during  the period  between December 2008 to April 2010.  
2.1.2. Study Population:  
A total   of  600  women   who  attended   the  above  mentioned   hospitals   are 
randomly   selected,  divided   into   two   groups,  pregnant   and   non-pregnant 
women (300 for each group).    
2.1.3. Collection of specimens:  
Five ml  of  blood  samples  were  obtained   from  each  subject   under   aseptic 
conditions. Sera  were  separated  and  stored  at -70 °C until the performance of 
tests.  
2.1.4. Study Location:  
This  study was conducted at  the  Microbiology Department   Elemies  National 
Hospital  in Sabia-Gizan,  Saudi  Arabia. Polymerase chain reaction (PCR) and 
89 
 
genotyping techniques were conducted at Alborg Laboratories, Jeddah, Saudi 
Arabia. 
2.1.5. The informed consent: 
All  participants  were  informed  about  the objectives of  the study, a quitianair 
form and written consent were filled by the participants in the study. 
2.2. Test methods: 
2.2.1. Immuno-chromatography test (ICT-ACON-San Diego USA):  
Procedure: 
1- The test device  was  removed  from  the  foil  pouch. 
2- A disposable  specimen’s  dropper  was   held  vertically  and  5µl of  a test    
   sample was transferred in each  well of  the test device.  
3-Two  full  drops (80 µl) of  provided buffer were added to the sample well.  
4-Timer was set at 10 minutes.  
A positive  result was  indicated by  the  presence of  a colored  line in  the  test 
region,  while   the  absence  of  a colored  line  indicated   a negative   result. A 
colored  line  always indicated that   the  proper volume of specimens has  been 
added.  
2.2.2. Enzyme Linked Immuno Sorbent Assay (ELISA):  
2.2.2.1. Indirect ELISA (Human reagents):  
Procedure:  
1-Two hundred µl  of  sample  diluents  were   dispensed in  all  required  wells  
    except the first well.                                       
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2- Ten µl of  negative control were added  in duplicate.  
3- Ten µl of  positive control  were added in triplicate.    
4- Ten µl of sample were added  in properly identified wells.  
5- The plate  was  mixed carefully  for 15  seconds and covered  with  adhesive  
    strips.                                                                                                                
6- The  plate was  incubated for 60 minutes at 37°C,  and washed 8  times  with 
      diluted  washing  buffer.   
7-The  remaining  washing  buffer  was   removed  by  taping  the  plate  gently  
    upside down on tissue paper.                                                                     
8- Hundred µl of  working  conjugate  were  added  and  mixed  carefully  for 15 
     seconds.  
9- The plate  was  incubated  for  30  minutes  at  37°C  and  the  conjugate  was 
     tipped off.  
10- The plate was washed 8 times with diluted washing buffer. 
11- After  washing, the  remaining  washing buffer  was  removed by taping  the 
      plate gently upside down on tissue paper.  
12- Hundred µl of working substrate were added, and mixed carefully.  
13- The plate was incubated at  room temperature (17-25°C ) for  30  minutes in 
      the dark.  
14- Hundred µl of stop solution were added and mixed.  
15-The  absorbance was   measured  in  a ELISA  plate reader  at  450 nm wave                     
length after 15 minutes.                                                                                                               
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16-The positive  control  and  the  positive  samples turned to yellow color, and                       
the intensity of  the  color  was directly proportional to the concentration of  the 
antibodies in the samples. 
Calculation of control values and Cut-OFF:  
The mean  absorbance values of  the negative control  (MNC)  in  wells  B1 
and C1  were calculated according to the equation:-  
MNC = A (B1) + A (C1) / 2  
The mean  absorbance values  of  the positive  (MPC)  control  in wells  D1, E1 
and F1 were calculated according to equation:-  
MPC = A (D1) + A (E1) + A (F1) /3  
The cut-off value (COV) = (0.25 X MPC) +MNC  
2.2.2.2. Second Line of ELISA Technique (Dia Pro Reagent):  
Procedure:  
1- The first well was left empty for the blank.  
2- Two  hundred µl of  the negative  control serum were dispensed in  triplicate  
   wells.                         
3- Two hundred µl of  the  positive  control  serum  were  dispensed  in a single 
     well.  
4-Two hundred µl of calibrator solution were dispensed in duplicate wells.  
5-Two hundred µl of  sample diluent were  added  to all sample wells.   
6- Ten µl of each sample were added in each sample well.   
7-The plate was gently mixed without over flow or contamination.  
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8- Fifty µl of  assay  diluent  were  added  in all  wells  including  negative  and  
   positive control wells to block the reaction.  
9-The plate was sealed with adhesive sealing foil and incubated for 45  minutes 
    at 37°C.                             
10- The plate was washed with  washing  buffer for 5 cycles.   
11-Hundred µl of enzyme conjugate were  added  in  all  wells  except  the first  
    well.   
12-The plate  was  sealed with  adhesive sealer and incubated  for 45 minutes at 
      37ºC.      
13-The plate was washed as before for 5 cycles.  
14- Hundred µl of  substrate mixture were added in all wells.   
15-The plate was incubated at room temperature for 15 minutes in the dark.  
16- Hundred µl of stop solution were added to stop the reaction.  
The positive control and the positive samples turn yellow in color, and the 
intensity of the color is directly proportional to the concentration of the HCV 
antibodies. 
Calculation:  
The  test  results  were  calculated   according  to   the Cut-off   value  which  is 
determined  by  the following formula and the results  were  based on the mean 
value of  the negative controls (MNC) at OD450 nm:  
    Cut-Off  Value (COV) = MNC + 0.350 
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Test results interpreted as  ratio of  the  sample  OD450nm  and  the  Cut-off  value 
(S/CO).  
2.2.3. PCR: 
3.2.3.1. Procedure:                                                                  
1-One  and  half  ml screw-caped clean and  sterile tube was labeled for  each     
   test    sample and two other tubes for  negative and positive control as (neg C, 
   pos C, S1, S2…..,S16).          
2- Four  hundred µl  of   working  lysis  reagent   were   added  to  each  of   the 
     labeled tubes (in step 1) and the tubes were recapped.                                  
3-Twenty  µl    HCV   negative   control   were   added   to   its    corresponding 
     labeled  tube, recapped   and vortexed for 3-5 minutes.                      
4-Twenty  µl    HCV   positive    control    were   added    to   its  corresponding 
    labeled  tube, recapped and  vortexed for 3-5 minutes.                      
5-Two hundred  µl of  each  patient specimen were added  to its  corresponding  
   labeled tube, the tubes were recapped and vortexed for  3-5 seconds.          
6- Specimens  and  controls  tubes  were  incubated  on  a dry  heat block for 10 
minutes at 60°C.                                                                                                  
7- All tubes were vortexed for at least 10 seconds.                                                
8-The  caps  were  removed  from  the   tubes  and   600 µl  absolute   isopropyl 
alcohol  were  added to each tube.                                                                      
9- The tubes were  re-caped, vortexed  for 3-5 seconds, and incubated  at  room 
temperature for 2 minutes.                                                                                  
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10- Specimens  and   controls   were  centrifuged  for  15  minutes  in   a micro-
centrifuge (Eppendorf-Germany)  at 14000/ rpm.                                             
11-The  supernatant  was  discarded carefully  by  using  new  fine  tips without 
disturbing the pellet.                                                                                         
 12-One ml of  70%  ethanol was  added  to  each tube, re-caped and vortexed    
     for 3-5 second.      
13-The tubes were centrifuged in a microcentrifuge for 5 minutes at 14000         
    rpm.                       
14-The supernatant was discarded by using fine new tips without disturbing the 
      pellet.     
15-The  tubes  were  recapped   and  centrifuged  at   maximum  speed  for   3-5 
     seconds and the supernatant was removed.  
16- Two hundred µl of  HCV diluent  were added  to  each  tube,  and  a part of  
     the  pellet was broken as  much as possible.   
17-The specimens were vortexed for 10 seconds, and stored frozen at -20°C as 
an extracted RNA for  HCV genotyping.        
18-The  appropriate  number  of  amplification  tubes were  determined  for 
patient  specimens and controls.   
19- Fifty µl of  working  master  mix  were  added  into  each A-Rings  using  
pipettor  with  aerosol  barrier (prepared immediately before use by adding 100 
µl of HCV manganese to one vial of HCV master mix).   
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20- Fifty µl of  each  processed specimen (extracted RNA) and controls were 
added to appropriate A-Rings containing master mix.  
21- The position of controls and specimens were identified in the A-Rings.  
22-The  A-Rings  were  placed  into  thermal cycler  segments of  the analyzer, 
and  the cover of  the thermal cycler segments was tightly closed .                        
23- The A-Rings were loaded   into  the  analyzer  ( COBAS  AMPLICOR-
Roche-Germany)   using barcode scanner.  
24-The reagents in the machine were checked (HCV probe suspension, 
substrate, denaturation solution  and  conjugate solution).  
25-The reagent racks were identified by using barcode scanner.           
26- The COBAS AMPLICOR was started.                                                            
Reverse transcription, amplification and detection are automatically performed  
by the analyzer. Results were  expressed  as  absorbance  value at  660 nm,  by 
comparing  the  specimens and  IC  absorbance (IC A660 more than  or  equal to  
0.15)  values, and  the analyzer  automatically  interpreted  results  as  positive, 
negative or equivocal.   
All samples that were PCR positive were used for genotyping.  
2.2.4. HCV Genotyping:  
3.2.4.1. Procedure: 
1-The PCR master mix was vortexed and centrifuged briefly.  
2- Thirty µl of the master mix were added to each reaction tube.  
3- Twenty µl of extracted RNA were added to the reaction tubes.  
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4-The tubes  were left  at  room temperature  for 10 minutes  prior  to  
amplification to allow degradation of any contaminated Uracil containing DNA.   
5- Biosystems Gene  AMP PCR  System 9700  thermal cycler (Eppendorf-
Germany)  was  used for reverse  transcription PCR (RT-PCR).   
6-The thermal cycler is calibrated before use, and optomized for use as follow:  
   1- Reverse Transcriptase                     at 50°c for 30 minutes.  
   2- Initial PCR Activation step              at 95°c for 15 minute.     
   3- Denaturation                                    at 95°c for 30 seconds.  
   4- Annealing                                          at 50°c for 30 seconds.  
   5- Extension                                           at 72°c for 15 seconds.     
   6-Repeat steps from 3-5 for 40 times (programmed in the thermo cycler).   
   7- Final Extension                                 at 72°c for 2 minutes.   
   8- Hold                                                    at 4°c not more than 2 hours.   
Due  to  the  potential  residual  activity  of  the  Uracil-N-glycosylase (UNG)  
after   amplification, RT-PCR samples have been stored for 2  hours at 4°c. 
HCV  genotyping was  done immediately  after  the removal of the  tubes  from 
 the  thermo cycler, .  
7-A waterbath (Eppendorf-Germany) with  a shaking  platform (80 rpm, 
temperature 50°c) and  a calibrated  thermometer were  used  to  ensure that  the 
samples  were well  shaken and  the temperature was adjusted at 50°c before 
adding the sample trays. 
8-An empty tray was inserted, and  the water level was adjusted  to  between    
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one third and half and of  the height of  the tray to  prevent the tray from sliding 
or floating by  immobilizing weight.  
9- The waterbath  shaking speed was adjusted  at 80 rpm without splashing of  
water in to the tray.  
10-The (LiPA) kit was removed from refrigerator (the VERSANT HCV 
Genotype v2.0 Assay, Siemens-Germany) and left  to reach room temperature 
before use.  
11-Hybridization and stringent wash solution (HYB/SW SOLN ) was placed in 
the waterbath at  50°c for at least one hour before use.   
12-The bottle containing washing solution was well shaken before use.   
13- Samples were checked and identified on  DATA REPORTING SHEETS.  
14-Clean plastic forceps were used  to  remove the appropriate number of  strips 
are (strip per sample) from  the  tube  by gripping each strip above  the green 
marker line, (15 strips in total: 13 for samples,   one  for the negative and one 
positive control).   
15-The top of each strip was labeled above  the green marker line with an 
identification number by using a pencil.  
16-Ten µl of  diluents  solutions  (DENAT SOLN)  were pipetted  into  the 
upper end of the trough.  
17-Ten µl of amplified DNA were  added to the DENAT SOLN and mixed 
properly by pipetting.   
18-Mixed solutions were incubated for 5 minutes.  
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19- Two ml pre-warmed HYB/SW solution were added to each trough. 
20-The strips  were placed  in the  troughs, the green  marker line facing 
upwards, and the solution was not allowed to spill from one trough to another. 
21-The waterbath shaker was turned off, and the tray in the waterbath was 
immobilized between two  heavy weights, and  the waterbath shaking was 
resumed at 80 rpm.  
22-The  strips were  moving  back  and forth  freely, and  their surface becomes 
completely submerged with the HYB/SW solution.   
23-The  lid  of  the   waterbath  was  closed  during  incubation  to   avoid  
change  of  temperature,  and  the hybridization incubation continued for 60 
minutes.  
24- The HYB/SW solution was incubated again in the waterbath at 50°c until 
the end of washing steps.  
25-The trays and the HYB/SW solution were removed from the waterbath.  
26-The tray was held at a low angle so that the liquid was accumulated at one  
end of  the troughs, above the green marker line of the strips for easy removal.   
27- The solution was aspirated from the trough by negative pressure.   
28- Two ml of  pre-warmed HYB/SW solution  were added to each  trough, the 
strip was  rinsed  by  rocking the  tray for  60 to 90 seconds  at  room 
temperature, and the solution was aspirated from each trough.  
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29-Washing  steps were  repeated  by adding  2 ml  pre-warmed HYB/SW 
solution to  each trough, the strip  was rinsed by  rocking  the tray for  60  to 90 
seconds, and the solution was aspirated from each trough.  
30-Two ml pre-warmed HYB/SW solution were added to each trough.  
31-The trays were incubated in the waterbath at 50°c and shaken at 80 rpm for 
30 minutes.  
32-The  trays  were  held  at  a low  angle so that the  liquid  accumulates at one 
end of  the troughs above  the green marker line for easy removal.   
33-Two ml of  diluted  rinse solution  were added  to each  trough, the strips  
were washed  by  rocking the  tray for 30-60 seconds, and the solution was 
aspirated from each trough.  
34-The above aspiration and washing steps were repeated.  
35-Two ml of  diluted conjugate were added  to each trough and the trays were 
placed on a shaker at room temperature for 30 minutes.  
36-The trays were removed from the shaker and the solution was aspirated from 
each trough.  
37-Two ml of diluted  rinse solution  were  added  to each trough and the strips 
were washed by rocking  the trays for 60-90 seconds  at  room  temperature and 
the solution was aspirated from each trough.   
38- The above aspiration and washing steps were repeated. 
39-Two ml of substrate  buffer (SUBS BUF) were added to each trough and the  
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strips were washed by rocking the tray for 60-90 seconds at room temperature, 
and  the solution was aspirated from each trough.  
40-Two ml of  diluted substrate were added to  each  trough, placed on a shaker 
at room temperature, and incubated for 30 minutes.  
41-The trays  were  removed  from  the  shaker,  and the solution was  aspirated 
from each trough.   
42-Two  ml  of  distilled  water  were  added  to  each  trough  to stop  the color 
development.   
43- The trays were placed on the shaker for at least 3 minutes.  
44-The trays were removed from the shaker, the water was aspirated, the 
washing and aspiration steps were repeated.  
45-Using clean forceps  the  strips  were  removed from the troughs and blotted 
on  a paper towel.  
46-The  strips  were  placed  on  the  data reporting sheet,   aligned  correctly 
with the marker line, and tapped down.  
47-The  strips were  placed  on  the  LiPA-SCAN reading teplate,  and were 
aligned correctly with the  conjugate line.   
48-The strips were dried completely before reading the result.  
49-The  numbers  of  the  lines in  the  strip  were  compared with  LiPA-SCAN 
reading teplate  and reported  in the data reporting sheet 
50- The identification of  HCV  genotype  and subtype was done by comparing 
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the  numbers  in  the  data  reporting  sheet  with   the   numbers  in  the   LiPA- 
interpretation chart. 
2.2.5: Statistical analysis: 
Analyses were performed with Statistical Package for Social Science (SPSS) 
with low significant difference (p = > 0.05). 
2.2.6:Ethical  clearance: 
A write consent was obtained from the patiants and the Health Ethical 
Committee , Gizan, Saudia Arabia  
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CHAPTER Three 
3. Results 
3. Result: 
3.1. ICT Result:  
Presence of  a red line in the test region indicated positive result  for  HCV.  The 
intensity of  the red color depends on the antibodies concentration in the sample. 
Any shade of red color in the test region treated as positive result and confirmed 
by more advanced method. Absence  of  this red line in the test region indicates 
 negative result.   
A red  line  should   appear in  the  control  region,  absence of  this line indicate 
invalidity of the result.       
600  samples  were  tested  against  HCV antibodies, 300 samples were pregnant 
and  300  were  non-pregnant  women. 17 samples  gave  a positive  reactivity to 
HCV  antibodies  ( Table. 5),  8  positive samples were  pregnant women and  9 
positive  samples  were  non-pregnant  women  (Table. 6).   All  s amples   were 
confirmed by ELISA techniques.  
3.2. ELISA tests Results: 
3.2.1 Human reagent: 
Positive  control and  positive samples  turn to yellow color, the  intensity of the 
color is directly proportional to the concentration of the antibodies. 
The absorbance  was  measured  at  A450, the  reference  wave  length  used  was 
620 nm.  
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Calculation of Control values and Cut-OFF: 
Mean  absorbance  values  of  negative  control (MNC) in wells B1 and C1 were 
calculated according to the equation:-  
MNC = A (B1) + A (C1) / 2  
Mean absorbance values of positive (MPC) control in wells D1, E1 and F1 were 
calculated according to equation:-  
MPC = A (D1) + A (E1) + A (F1) /3  
Cut-off value (COV) = (0.25 X MPC) +MNC 
Results were  interpreted  as follows: A450 < COV , the  result  was non-reactive, 
A450  more than or equal to COV the results were reactive and need tobe retested 
for  confirmation. If  the  results  were  1.0 <S/CO <1.5  it  were  interpreted   as 
equivocal result, need to be repeated and confirmed.  
A total of 600 samples were tested against HCV antibodies, 14 samples  showed 
reactivity  to  HCV  antibodies, 6  were  pregnant,  8 were non-pregnant women, 
and 2 samples showed equivocal results, one sample for each group.  
3.2.2. DiaPro reagent: 
 
The test results were calculated by means of a cut-off value determined with the 
following formula  on  the  mean  value of  the negative controls at  OD450 nm:  
    Cut-Off (Co) = MNC + 0.350 
Test results were interpreted as a ratio of the sample OD450 nm and  the Cut-off  
value (S/CO), and as negative, positive or equivocal. Negative  results should be 
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< 0.9,  while  positive  results should  be  >1.1.  Equivocal  results were between  
0.9 - 1.1. 
A total of 600 samples were tested against HCV antibodies, 14  samples showed 
 reactivity  to  antibodies,  6  were  pregnant,  8  were non-pregnant women, one 
sample (non pregnant group) showed equivocal result . 
3.3. PCR Result: 
Results were expressed as absorbance value at 660 nm and as Positive, Negative 
or  Equivocal. The  results  were  interpreted  by  comparing  the  HCV  and   IC 
absorbance values, the analyzer automatically interpreted specimens as  follows: 
Specimens with an HCV A660  less than 0.15 and an  IC A660  more than or equal 
to  0.15,  the result of  the  specimens  was interpreted  negative (HCV RNA not 
detected),  while IC result was positive  (A660 more than or equal to  0.15).  If an 
HCV A660  more  than or equal to 1.0, the  result  interpreted  positive  and  HCV 
RNA was  detected. As a quality  control  for  this  procedure, the  result  of  the 
negative control A660 must be less than 0.1, and the positive control A660  should 
be greater than or equal to1.0.   
16   samples  processed, 13   samples  gave  a reactive  result,  6  samples   were 
pregnant, 7  were non-pregnant  women  and   3  samples   gave   a non- reactive 
result  by COBAS AMPLICOR analyzer. 
  
3.4. Genotyping result: 
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Identification of  the  patients  began  with  the  group  number  followed  by the 
patient  code  number, then  the number in the strip. The numbers of  the lines in 
the strip compared with  LiPA-SCAN READING TEPLATE, and  the  numbers 
were  reported   in  the  DATA  REPORTING  SHEET. Identification   of  HCV 
genotype    and   subtype  were  done  by comparing   the  numbers  in   the  data 
reporting sheet with the numbers in the LiPA- Interpretation Chart. 
Pregnant women  (group 1) testing showed that 4 patients belonged which geno-
type 4, while one  patient  belonged which genotype 4 subtype a, b or c, and one 
patient  also  showed  genotype 1  subtype b. The  other  group of  non-pregnant 
women (group 2) showed that 3 patients were genotype 4, other 3  patients were 
from genotype 4 subtype a, b or c, while one patient  was  genotype 1 subtype a.  
The results showed that the main genotype among the two group  was  genotype 
4 with different subtypes.  
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Table No 5:  Distribution of HCV antibody results among pregnant women 
  
Tests Method Total   
samples No
Positive 
results 
Percentage  Equivocal 
results 
Screen test (ICT)
 
300 8 2.7 0 
Human Reag 
 
300 6 2.3 1 
Dia pro Reag 
 
300 6 2 0 
PCR Test 
 
300 6 2 0 
 
P value = > 0.05 
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Table No 6:  Distribution of HCV antibodies results among non-pregnant 
women 
 
Tests 
Method
Total   
samples 
No
Positive 
results
Percentage Equivocal 
results
Screen test 
(ICT)
300 9 3 0 
Human Reag 300 8 3 1 
Dia pro 
Reag
300 8 3 1 
PCR Test 300 7 2.3 0 
 
P value = > 0.05 
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4. Discussion 
4.1. Discussion: 
 
Hepatitis C virus (HCV) is a major public health problem and a leading cause of 
chronic liver disease. The WHO estimated a worldwide prevalence of  3%  with 
virus affecting 180 million people worldwide (372).   
The population  in Saudi Arabia is  homogenous in culture and tradition, and the 
level of social and economic development remains uneven. Gizan  population is 
a rural  area  with  the  water  supply  and  sewage disposal  systems  not  as  yet 
developed  as  in  the  urban  areas of the country (373,374). Furthermore, there is a 
constant  influx  of  immigrants from  neighboring countries such as Yemen and 
Somalia. The interaction of native Saudis with these expatriates may explain the 
relatively  significant  increase  in  prevalence  of   viral  hepatitis such  as HBV, 
HAV and HEV (375). 
The parentally-transmitted  HCV  is  of a major interest and importance because 
of  the  associated  relatively  high  frequency  of  sequelae such as chronic liver 
disease, cirrhosis and hepatocellular carcinoma (HCC), which increased sharply 
over  recent  decades  and  had  been  attributed  to  chronic  HCV infection (216). 
Serological markers of HCV infection in patients with HCC range from 27% up 
to  80%,  and  HCV  infection  increases  the  risk  of  HCC  development  by an 
estimated  17-fold  compared  to  healthy  individuals  (216).  The  prevalence   of 
hepatitis B in Gizan region was reported as 12-28% (376). In contrast, antibody to 
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hepatitis C  among  healthy  Saudi  Arabs  population is about 1.8 to 3% varying 
from one region to another (373,377). 
A number of  studies  have  demonstrated  that  the  rate of transmission of HCV 
from  infected  mothers  to their offsprings is low (averaging 5%) (378).  In  HCV 
patients co-infected with human immunodeficiency virus (HIV), HCV viral load 
is  high,  and  duration of  labor  is  longer  were reported and recognized as risk 
factors. However, little  is  known  about the risk of vertical transmission during 
subsequent pregnancies, particularly among  women  without  HIV co-infection. 
Mothers  whose babies  were  born with HCV infection might not wish to go for 
another pregnancy due to fear of having another HCV-infected baby (379). 
However, there is no published  data  concerning  the  prevalence of  hepatitis C 
infection among pregnant  women  in  Sabia, Gizan. Reports  from Saudi Arabia 
showed that prevalence of hepatitis C virus infection ranged from 1.0%  to 5.0% 
(380). In a community based study, among Saudis aged 10 to 50  years  in  Gizan, 
anti-HCV positivity  ranged  between  1.9% to 3.5%  and increased  with  age in 
people over 50 years (381).   The  geographical  distribution  of  a whole  endemic 
region in a neighboring country might change the current situation as  in  Egypt; 
the prevalence  of  HCV among  pregnant  women  was  (9.8%)  which  is much 
higher in  comparison  to  our  study  due to heavy  burden of schistosomiasis in 
Egypt. Moreover,  needle  sterilization  was  inadequate, and  disposable needles 
were unavailable  at  that time. They  resulted  in  widespread of  HCV infection 
through  reuse  of  contaminated  needles (382).  Prevalence  in  Yemen was 2.1% 
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among  pregnant  women (383)  and that was in agreement with our study because 
Gizan  was once  a national  extension  of   Yemen, with  the  same  culture  and 
tradition  and  the  same level of  socioeconomic  status.  Furthermore, there  is  a 
constant  influx of  immigrants  from  Yemen,  and  their  interaction with native 
Saudis  may  explain  the relative  similarity  in  HCV  prevalence  between both 
countries.  In  Sudan  the  prevalence  of  HCV   among   pregnant   women  was 
0.2% (384)  which is much lower in comparison to our study. That  may be due to 
the difference in diagnostic tools or to the difference in life  style  between these 
communities  that may affect the methods of virus transmission, and the level of 
 health education in comparison to that in Gizan region. 
In  other  studies  conducted  in  other  regions  of  Saudi  Arabia  to  assess   the 
prevalence  of  anti-HCV  among  Saudi  pregnant  women  a prevalence  rate of 
6.7%  in  Makkah  and  4.6%  in  Riyadh was reported (380). This is in contrast to 
what we found in Gizan region (2%).  Disagreement  in  these  results  could  be 
attributed  to  the  transmission factors such as high risk behaviors in addition to 
the   heavy  cosmopolitan   population  of  these  area. The interaction  of  native 
Saudis with these expatriates may explain the relatively  significant  increase  in 
 prevalence in these area, or due to the improvement of  diagnostic tool  used  in 
this study (PCR). The prevalence in Jeddah was 2.7% (380)  that was in agreement 
with our result, and may be due to the use of a sensitive diagnostic tool or to the 
fact  that  Jeddah  city  acts  as entrance of   Saudi Arabia, in  which  immigrants 
from   neighboring  countries   enter  Saudi  Arabia  such  as  Gizan.   Estimated 
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prevalence in  the  Eastern  province  was  1% (385). This result differed from our 
result  and  that can also be due to the difference in the diagnostic tools or in the 
level of  socioeconomic  development  (Gizan still under developing rural area), 
also  there  is  a high  degree of   variation in the mixture of the local population. 
HCV   genotypes  varied   worldwide  according   to  the   geographical   region. 
Genotype 4 causes approximately 20% of global infection. It is  predominant  in 
the Middle East, Egypt, and  Central  and West Africa  (Zaire, Gabon, Tanzania, 
Cameroon, Central Africa Republic) (386). In Saudi Arabia the most predominant 
is  genotype  4 (62%)  followed  by  genotype  1 (24.1%),  2 (7.4%), 3 (5.9%), 5 
(0.3%),  and 6  (0.3%) (387).  In  Riyadh the predominant is genotype 4 (60%), 1b 
(21.4%), 1a (14.3) and 2a (3.6%). Therefore, all regions in Saudi Arabia showed 
the  similar  distribution of  HCV genotyping, while there is no difference in the 
genotype distribution patterns between sex and age (387). I n comparison with the 
present study, the major genotype present among pregnant women is genotype 4 
(83.3%)  with  subtypes  4,  4a,  4b  or  4c.  However,  genotype  1 subtype  (1a) 
prevalence  is  (16.7%),  on  the  other  hand,  the  major  genotype  among non-
pregnant  women  was  genotype  4  (85.7%)   with  subtypes  4,  4a,  4b  or   4c. 
However,  genotype  1  subtype  (1b)  accounts   for  14.3%.  Our  finding  is  in 
agreement   with   national  study  in  Saudi  Arabia. This similarity between the 
present  study  and  national  and regional studies might be aconsequence of  the 
same  source of   infection (387). Genotype  4  is  associated  with   pathogenicity, 
disease  severity,  response  to  antiviral  therapy,  liver  fibrosis  and  eventually 
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hepatocellular  carcinoma.  However,  the  present  study  despite  the  fact it has 
been carried out in the least developed region of the Saudi Arabia  (the Southern 
region),  it  may  open  the way  to  other  studies to elucidate HCV genotypes in 
other regions of Saudi Arabia. 
Conclusion: 
1- Hepatitis C virus antibodies were detected in both pregnant and non-pregnant 
     women, although the difference was not statistically significant.  
2-The main genotype detected was genotype 4, followed by genotype 1.  
3-The route of HCV transmission based on a questionnaire was not that clear.   
Recommendations: 
An  effective  vaccine  against  HCV  infection  is  still  not  available;  thus, the 
control of HCV infection becomes difficult; and therefore, the following control 
measures could be adopted by the Health authorities: 
1- Continuous mandatory screening of all blood donors by NATS tests. 
2- Vigorous public health campaign by the Health authorities to reduce the    
practice of folk medicine where improperly sterilized instruments are used. 
3-Post exposure testing of individual for anti-HCV antibodies, and if turned to 
be reactive, should be retested for HCV-RNA by PCR-based assays. 
4-Early treatment of HCV should be implemented for positive HCV –RNA 
individuals if they show any signs or symptoms. 
5-Large epidemiological studies should be carried out to assess the feasibility, 
effectiveness, and cost-effectiveness of antenatal screening program. 
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6-The relatively  high prevalence rate of anti-HCV in Saudi pregnant women, 
made it necessary for the health authorities to include anti-HCV screening tests 
into the pre-marital screening program.  
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Appendices 
Appendix 1: 
Conjugate: 
Anti human IgG bound horse radish peroxidase  
0.1 +phosphate buffer saline                                 pH 7.0   
Coloured blue  
Appendix 2: 
Conjugate diluents: 
0.1 +Tis buffer                                                           pH 7.0   
Tween 20                                                           0.2% 
Working conjugate solution: 
Conjugate   was  diluted 1+20 with conjugate diluents 50 µl of conjugate to 
1000 µl of conjugate diluents, prepared fresh before work  and  mixed well 
before use.    
Appendix 3:   
Washing buffer: 
1.0 +Concentrated phosphate buffer saline   Ph 6.5  
Tween 20                                                       0.2% 
Working washing solution: 
Wash  buffer (WS)  was diluted with fresh distilled water (DW) 1+19, 50 ml 
WS + 950 ml DW, then the content was mixed before use. 
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Appendix 4:  
Substrate A:  
Hydrogen peroxide                                  0.03% 
Citric acid buffer                                       0.06 mol/l 
Appendix 5: 
Substrate B: 
3,3`,5, 5`-tetramethyle benzidin (TMB)  0.6 g/l 
DMSO                                                            0.7 mol/l 
Working substrate: 
Working substrate was prepared by mixing equal  volume of  substrate A  and 
substrate B.  
Appendix 6: 
Sample diluents: 
0.1 +Tis buffer                                                           pH 7.0  
Tween 20                                                           0.2% 
Appendix 7: 
Negative control: 
Human serum negative for HCV 
Appendix 8: 
Positive control:  
Human serum positive for HCV  
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Appendix 9: 
Stop solution: 
Sulphuric acid                                                      1.0 mol/l 
Working washing buffer: DIAPRO 
Concentrated  washing  phosphate buffer  60 ml was diluted with  distilled 
water up to 1200  ml, and  mixed  well before  use  to  dissolve all salt crystals 
may  present in the vials. 
Appendix 10: 
Negative control: 
Goat serum protein negative for HCV                    1% 
Appendix 11: 
Positive control 
Human antibodies positive to HCV 
Goat serum protein                                                 1% 
0.1)                             10%  +Na citrate buffer (pH 6.0  
Tween 20                                                                0.5% 
Na azide                                                                  0.9% 
Kathon GC                                                               0.1%  
Appendix 12: 
Calibarator: 
Foetal bovine serum proteins 
Human antibodies to HCV (Standardized) 
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0.1)                       +Na citrate buffer (pH 6.0  
Gentamycin sulphate                                           0.3 mg/ml 
Kathon GC                                                          0.1%  
Appendix 13: 
Sample diluents: 
Goat serum protein                                             1% 
0.1)                           10%   +Na citrate buffer (pH 6.0   
Tween 20                                                          0.05% 
Na azide                                                           0.09% 
Kathon GC                                                      0.1%  
Appendix 14: 
Assay diluents: 
0.1)               10%    +Tris buffer solution (pH 8.0   
Kathon GC                                                    0.1%  
Appendix 15: 
Enzyme conjugate: 
Horse Radish Peroxidase conjugated to polyclonal antibodies to human IgG and 
IgM 
BSA                                                                 5% 
0.1)                              10%   +Tris buffer  (pH 6.8   
Kathon GC                                                     0.1%  
Gentamycin sulphate                                      1% 
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Appendix 16: 
Substrate: 
Dimethyl sulphoxide                                     4%    
Tetra Methyl Benzidine                                0.03% 
Citrate phosphate buffer (pH 3.5-3.8)         50 mM  
Appendix 17: 
HCV internal control: 
Transcribed RNA                                      0.001% 
containing HCV primer binding sequence and probe binding region.  
Appendix 18: 
HCV Lysis reagent: 
Guanidinethiocyanate                             68% 
Dithiothreitol 
Polyethylene glycol 
Working  lysis  reagent  was  prepared  by  adding  100 µl  o f  HCV  Internal  
Control (appendix 17) to one bottle of  HCV  lysis (appendix 18).  
Appendix 19: 
Negative control: 
Poly r A RNA synthetic                              0.005% 
Sodium Azide  
Appendix 20: 
Positive control: 
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Transcribed RNA contain HCV sequence          0.001% 
Sodium Azide 
Controls  were  prepared by  vortex the negative human plasma (NIH), HCV  
negative control and  HCV  positive control  for 5-10 second,  and then  200 µl 
of  NHP  was  added  to  each of the  two controls tubes, then tubes were capped 
and vortex for 3-5 minutes.                                               
Appendix 21: 
HCV diluents: 
Poly r A RNA synthetic                            0.005% 
Sodium Azide 
Appendix 22: 
HCV Master mix: 
rTth DNA polymerase                     0.01%    
d NTPs (d ATP,d GTP, d CTP and d UTP)                  0.001%   
KY80 (5`-GCA GAA AGC GTC TAG CCA TGG CGT-3`)  0.005% 
KY78 (5`-CTC GCA AGC ACC CTA TCA GGC AGT-3`)   0.005%    
Uracil-N-Glycoslase                         0.01%  
Bicine buffer 
Dimethyl Sulphoxide (DMSO) 
Glycerol 
Potassium acetate 
Sodium Azide 
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Working Master Mix by adding HCV Mn2+   (Manganese acetate  tetrahydrate + 
Sodium Azide) to Master Mix solution. 
Appendix 23: 
HCV probe suspension   
CX PSI  cassette                                         0.4%  
(HCV probe suspension 1 contain  magnetic Dynabeads coated with HCV- 
specific oligonucleotide capture probe KY150  5`-
CATAGTGGTCTGCGGAACCGG TGA GT -3`) 
4-Morpholineethanesulphonic acid (MES) buffer  
Boric acid 
Sodium chloride 
Tween 20 
Sodium Azide   
CX4   cassette  
(HCV probe suspension 2 contain 42.2% Sodium thiocyanate + Sodium 
phosphate, monobasic, monohydrate)  
Probe suspension was prepared by adding 2.5 ml of  CXPSI  to one cassette 
CX4. 
Appendix 24: 
HCV substrate: 
Substrate B (SB contain 0.1% 3, 3, 5, 5` Tetramethyl benzidine TMP and 40% 
Di- methylformamide DMF)  
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Substrate A (SB3) cassette (Citrate solution contain 0.01% Hydrogen Peroxide 
and 0.1%  proclin 150)  
Working HCV substrate was prepared by adding 5 ml of substrate B in to one 
cassette of substrate A cassette. 
Appendix 25: 
HCV denaturation   solution (DN4) 
Sodium Hydroxide                               1.6% 
Thymol blue  
EDTA disodium dihydrate  
Appendix 26: 
HCV conjugate solution  (CN4):  
Avidin-Horseradish Peroxidase Conjugate          0.001% 
Tris-HCL buffer solution 
Bovine serum albumin 
Emuliset 25 
Phenol 
Proclin 150  
Appendix 27: 
HCV Master Mix (gentyping): 
-Prepare the Master Mix by adding 290 µL of AMP MIX (contains synthetic 
oligonucleotide in buffer with d NTP and d UTP mixed with Manganese 
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Chloride and RNAsin) to one vial of ENZ MIX (contains synthetic reverse 
transcriptase, Hot Star Tag polymerase and Uracil-N-Glycosylase). 
-For any number of sample use the equation (N X 26 µL AMP MIX) is added to 
(N X 4 µL ENZ MIX) where N = number of samples, including 1 positive and 1 
negative control + 1. 
(13 samples +1 positive control + 1 negative control + 1 =16 sample).  
2-Add 16 x 26 = 416 µL OF AMP MIX to 16 x 4 = 64 µL ENZ MIX.  
Appendix 28: 
Hybridization and Stringent Wash Solution 
Sodium Chloride  
Sodium Citrate buffer  
Appendix 29: 
Diluents  solution  DENAT SOLN 
Sodium Hydroxide                               1 .7% 
Appendix 30: 
Rinse solution: 
2-Chloroacetamide                  0.5% 
NaCl 
Phospate buffer 
Detergent 
Preservative 
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-Concentrated rinse solution should be diluted 1:5(1 part + 4 parts) with  
distilled water to make the diluted rinse solution. Prepare 8 ml diluted rinse 
solution for each test trough and 10 ml extra, for 15 samples (26 from RINSE 
SOLN + 104 ml from distilled water).   
 Appendix 31: 
Conjugate 
Striptavidin-labeled with alkaline phosphatase 
2-Chloroacetamide  
Protein stabilizers 
Preservative 
-Concentrated conjugate should be diluted 1:100 in conjugate diluents (contain 
phosphate buffer with 2-Chloroacetamide and protein stabilizers and 
preservative),  to make diluted conjugate solution, prepare 2 ml diluted 
conjugate for each test trough and 2 ml extra, for 15 samples (32 ml conjugate + 
320 ml CONJ DIL). 
Appendix 32:  
Substrate buffer (SUBS BUF): 
buffer Tris 
2-Choloracetamide           0.1% 
NaCl  
MgCl2 
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Appendix 33: 
 Substrate (BCIP/NBT) 
5-Bromo-4-cholro-3-indolyl-phosphate     1.6% 
4-Nitroblue tetrazolium  
Dimethylformamide     83% 
Concentrated Substrate should be diluted 1:100 in Substrate Buffer,  Prepare 2 
ml diluted substrate for each test trough and 2 ml extra, for 15 samples (32 ml 
substrate + 320 ml substrate buffer). 
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